

## Scientific Program

### BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00  
Thursday, October 9

Chair Persons: P.J. Pollard, M.-H. David-Cordonnier, D.J. Richard

111. The role of fumarate as an oncometabolite. **P.J. Pollard** (Edinburgh, UK) (25')
147. Targeting transcription factor at the DNA binding level: Inhibition of ERG and FLI1 binding to their consensus DNA binding site. R. Nhili, S. Depauw, M. Lambert, M.A. Bouhlel, **M.-H. David-Cordonnier** (Lille, France) (25')
520. hSSB1, a critical DNA repair protein in cancer development. **D.J. Richard**, N. Paquet, V. Leong, M. Adams (Brisbane, Australia) (25')
511. Cell cycle regulation in cancer stem cells and iPS cells - The role of PFKFB3. **A. Cieslar-Pobuda**, S. Ghavami, E. Wiechec-Los (Linköping, Sweden; Winnipeg, Canada) (25')
250. The roles of transcription factor CCAAT/enhancer binding protein delta in tumorigenesis. Y.-W. Hsiao, J.-Y. Chi, **J.-M. Wang** (Tainan, Taiwan, R.O.C.) (20')

### SIGNAL TRANSDUCTION

Room A, 11:30-13:30  
Thursday, October 9

Chair Persons: C.M. Wells, S.-A. Stephenson, N.S. Duesbery

127. PAK family kinases - Molecular targets in cancer metastasis. S. Fram, H. King, **C.M. Wells** (London, UK) (30')
138. Effective signaling in cancer: Understanding the complex roles of EphB4 in oncogenesis and tumour suppression. J.E. Lisle, I. Mertens-Walker, M. Maharaj, C.R. Stephens, A.C. Herington, **S.-A. Stephenson** (Brisbane, Australia) (30')
395. MKK signaling in angiosarcoma. N.J. Andersen, E.A. Boguslawski, **N.S. Duesbery** (Grand Rapids, MI, USA) (30')
172. Autocrine signaling plays a major role in the response of colorectal cancer cells to VEGF blockage. **A.K. Larsen**, V. Poindessous, M. Sabbah, A. De Gramont, P. Mésange (Paris, France) (30')

## CANCER THERAPEUTICS

Room A, 15:30-17:30  
Thursday, October 9

Chair Persons: P. Fishman, M.R. Sanderson, P.Z. Anastasiadis

279. CF102 for the treatment of liver cancer: De-regulation of the Wnt signal transduction pathway. **P. Fishman** (Petach-Tikva, Israel) (30')
380. Type II topoisomerases as targets for rational drug design. I. Laponogov, D.A. Veselkov, T. Umrekar, I.M.-T. Crevel, X.-S. Pan, J. Selvarajah, L.M. Fisher, **M.R. Sanderson** (London, UK) (30')
508. Src family kinases differentially affect human gliomas: Implications for therapy. L.J. Lewis-Tuffin, R. Feathers, P. Hari, N. Durand, Z. Li, K. Bakken, B. Carlson, M. Schroeder, J. Sarkaria, **P.Z. Anastasiadis** (Jacksonville, FL; Rochester, MN, USA) (30')
473. Role of muscarinic receptors in tumors: Possible therapeutic implications. M. Di Bari, I. Cristofaro, F. Alessandrini, V. Tombolillo, M. Fiore, L. Conti, A. Calogero, **A.M. Tata** (Rome; Trento; Latina, Italy) (30')

## microRNAs

Room A, 18:00-20:00  
Thursday, October 9

Chair Persons: R. Gambari, A.P.N. Majumdar

489. Targeting the microRNA-transcription factor network for innovative therapeutic protocols for  $\beta$ -thalassemia and sickle-cell anemia. **R. Gambari** (Ferrara, Italy) (30')
133. microRNA regulation of colon cancer stem cells. **A.P.N. Majumdar** (Detroit, MI, USA) (30')
478. Recombinant adeno-associated virus-based microRNA therapeutics for cancer. J. Xie, Q. Mao, Y. Zhang, J. Ai, B. Han, D. Gutierrez, P.D. Zamore, **G. Gao** (Worcester, MA; Chevy Chase, MD, USA; Sichuan, P.R. China) (30')
302. Diagnostic role of circulating miRNAs in coronary artery disease patients. **A.S. Md Sayed**, K. Xia, F. Li, X. Deng, U. Salma, T. Li, T.L. Yang, J. Peng (Changsha, P.R. China; Boston, MA, USA) (30')

## IMMUNOLOGY/MOLECULAR ONCOLOGY

Room B, 09:00-11:00  
Thursday, October 9

Chair Persons: S. von Gunten, S.N. Karagiannis, L. Vannucci

157. Altered surface glycosylation with expression of Siglec-7/-9 ligands protects tumors from NK cell immunosurveillance. C. Jandus, K.F. Boligan, O. Chijioke, H. Liu, M. Dahlhaus, T. Démoulins, C. Schneider, M. Wehrli, R.E. Hunger, G.M. Baerlocher, H.-U. Simon, P. Romero, C. Münz, **S. von Gunten** (Bern; Zurich; Mittelhäusern; Lausanne, Switzerland) (20')
425. Engineered IgE antibodies recognising tumour associated antigens: A paradigm for activating immune effector functions against cancer. **S.N. Karagiannis**, D.H. Josephs, H. Bax, P. Karagiannis, L. Saul, T. Dodev, P.J. Blower, A.J. Bevil, H.J. Gould, J.F. Spicer (London, UK) (20')
485. Immune activation by microbiome shapes the stroma of the bowel in healthy and pathological conditions differently. **L. Vannucci**, J. Krizan, F. Caja, D. Stakheev, L. Rajsiglova, P. Okenfuss, J. Dvorak, O. Chernyavskiy, R. Stepankova, H. Kozakova, P. Vodicka, V. Vymetalkova Polakova, V. Horak, J. Janda, M. Levy, R. Matej, P. Makovicky, P. Rossmann (Prague; Libechov, Czech Republic) (20')
329. Cancer immunotherapy: Targeting tumors expressing mutant p53. **B. Solomon** (Tel-Aviv, Israel) (20')
449. Detection of anti-HLA antibodies: From past to present. P.K. Saito, R.H. Yamakawa, **S.D. Borelli** (Maringá, Brazil) (20')
592. IgE-based immunotherapy of cancer - A comparative oncology approach. **J. Singer**, J. Fazekas, W. Wang, M. Weichselbaumer, M. Matz, A. Mader, W. Steinfeldner, S. Meitz, D. Mechtcheriakova, Y. Sobanov, T. Stockner, E. Spillner, R. Kunert, M. Willmann, J. Thalhammer, E. Jensen-Jarolim (Vienna, Austria; Beijing, P.R. China; Hamburg, Germany) (20')

## CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:30  
Thursday, October 9

Chair Persons: T. Hattori, R. Guerrero-Preston

240. Development of Barrett's Esophagus - A novel GRCL (gut regenerative cell lineage) theory. **T. Hattori**, T. Nakayama, K.-I. Mukaiho (Otsu, Japan) (25')
426. Key tumor suppressor genes inactivated by promoter methylation and somatic mutations are associated to survival disparities in head and neck cancer. **R. Guerrero-Preston**, C. Michailidi, L. Marchionni, C. Pickering, M. Frederick, J. Myers, S. Yegnasubramanian, T. Hadar, M.G. Noordhuis, E. Fertig, N. Agrawal, W. Westra, W. Koch, J. Califano, V.E. Velculescu, D. Sidransky (Baltimore, MD; Houston, TX, USA; San Juan, Puerto Rico; Groningen, The Netherlands) (20')
149. CD97iso: A novel therapeutic marker for metastatic gastric carcinoma. **D. Liu**, B. Trojanowicz, C. Li, X. Li, L. Chen (Hangzhou, P.R. China; Halle, Germany) (15')
223. New predictive markers of response to chemoradiotherapy in rectal cancer: miR-17-92 and methylation profile. **C. Molinari**, S. Salvi, E. Carretta, N. Teodorani, A. Passardi, A. Avanzolini, L. Saragoni, W. Zoli, D. Calistri (Meldola; Forlì, Italy) (15')
469. Tumour-derived microvesicles as important players in tumour-immune cells interactions. **M. Baj-Krzyworzeka**, R. Szatanek, J. Baran, B. Mytar, M. Siedlar (Cracow, Poland) (15')
265. Involvement of RuvBL2 in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells. Q. Zhan, **S.-M. Ngai** (Hong Kong, P.R. China) (15')
574. miRNA microarray reveals specific expression in the peripheral blood of glioblastoma. **L. Dong**, Y. Li, X. Wang, H. Zhang, C. Han (Yangzhou, P.R. China) (15')

## METASTASIS/PROGRESSION

Room B, 15:30-17:30  
Thursday, October 9

Chair Persons: R. Probstmeier, H. Du

306. The limitless proliferative capacity of cancer cells and how to limit it. **R. Probstmeier**, J. Winter, D. Kraus (Bonn, Germany) (30')
352. Myeloid-derived suppressor cells with lysosomal acid lipase deficiency stimulate cancer cell proliferation and metastasis through activation of the mTOR pathway. **H. Du**, T. Zhao, X. Ding, C. Yan (Indianapolis, IN, USA) (30')
521. Selective stimulation of HER-2/HER-3 signaling-pathway triggers FOXA1 and confers hormone resistance in breast cancer. M.R. Katika, S. Gilfillan, S. Norhagen, E. Fiorito, B. Bai, E. Gonzalez, Y. Sharma, A.-L. Børresen-Dale, **A. Hurtado** (Oslo, Norway) (30')
131. Prohibition of tumor cell migration by combined hnRNPK-knock down and irradiation. **J. Brieger**, J. Strozynski, N. Wiesmann (Mainz, Germany) (15')
434. FOXM1 promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of uPAR and Caveolin-1. **C. Huang**, Z. Qiu, K. Xie (Shanghai, P.R. China; Houston, TX, USA) (15')

## APOPTOSIS/HYPOXIA

Room B, 18:00-20:00  
Thursday, October 9

Chair Persons: E. Agostinelli, K. Takács-Vellai

185. Potentiation of cytotoxicity of spermine metabolites induces apoptosis in tumor cells: Proteomic studies and new approaches in cancer therapy. G. Tempera, C. Barrero, G. Pepe, S. Ohkubo, P. Matricardi, S. Merali, **E. Agostinelli** (Rome, Italy; Philadelphia, PA, USA) (25')
234. Characterizing the role of the NM23 homolog NDK-1 in cell migration and apoptotic engulfment. L. Fancsalszky, Z. Farkas, M.H. Bosnar, T. Vellai, A. Mehta, **K. Takács-Vellai** (Budapest, Hungary; Zagreb, Croatia; Dundee, UK) (20')
193. Apoptotic protein activation and immune activation of turmeric oil component *in vitro* and *in vivo* research. D. Kim, H. Lee, K. Hong, **Y. Lee** (Busan, Republic of Korea) (15')
236. The role of ANP32B in leukemic cell apoptosis and differentiation. **Y. Yu**, S.-M. Shen, L.-S. Wang (Shanghai, P.R. China) (15')
313. Establishment of hypoxia induction in an *in vivo* animal replacement model for experimental evaluation of pancreatic cancer. **N. Bauer**, L. Liu, E. Aleksandrowicz, I. Herr (Heidelberg, Germany) (15')
444. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF- $\kappa$ B downregulation. **L. Liu**, A.V. Salnikov, M.W. Büchler, I. Herr (Heidelberg, Germany) (15')
500. The effect of hypoxia on human skeletal muscle: Molecular and cellular analysis. **R. Mancinelli**, V. Verratti, C. Doria, S. Fulle, T. Pietrangelo (Chieti-Pescara, Italy) (15')

## EXPERIMENTAL CARCINOGENESIS

Room C, 09:00-11:00  
Thursday, October 9

Chair Persons: N. Cheng, M.Z. Ratajczak, S.-L. Yang

108. A retrospective cohort mortality study in Jingchuan of China - The largest nickel population in the world. **N. Cheng**, L. Ma, T. Zheng, H.Q. Pu, J. He, M. Dai, Y. Zhang, Y. Bai (Lanzhou; Jinchuan; Beijing, P.R. China; New Haven, CT, USA) (30')
109. Identification of the extracellular nucleotides ATP and UTP as novel underappreciated pro-metastatic chemotactic factors for human lung cancer cells. **M.Z. Ratajczak**, A. Poniewierska, M. Tarnowski, J. Ratajczak, G. Schneider (Szczecin, Poland; Louisville, KY, USA) (30')
201. Identification of new roles of HIF-2 alpha in the development of hepatocellular carcinoma. **S.-L. Yang**, S.-C. Yang, R.L.K. Ho, Y. Sun, X. Yang, J. Fan, J.-W. Ren, X. Fang, G.G. Chen, P.B.S. Lai (Hong Kong; Shanghai, P.R. China; Gainesville, FL, USA) (30')
466. DNA demethylation in stem cells and cancer development. **F. Neri**, A. Krepelova, D. Incarnato, D. Dettori, M. Maldotti, S. Rapelli, C. Parlato, S. Oliviero (Torino, Italy) (15')
539. Pon1 polymorphism and biomarkers of oxidative stress in workers exposed to pesticides. C. Costa, **S. Gangemi**, F. Giambò, V. Rapisarda, C. Fenga (Messina; Catania, Italy) (15')

## MOLECULAR ONCOLOGY/CLINICAL ONCOLOGY

Room C, 11:30-13:30  
Thursday, October 9

Chair Persons: B. Baron, S.-T. Lee

256. Characterising the biological function of E4TF1-binding methyltransferase (EBM) in cancer. **B. Baron**, Y. Kuramitsu, T. Kitagawa, K. Nakamura, P. Schembri-Wismayer (Msida, Malta; Ube, Japan) (25')
590. Differential oncogenic roles of a defective receptor tyrosine kinase, PTK7, before and after shedding. W.-S. Shin, H.-W. Na, **S.-T. Lee** (Seoul, Republic of Korea) (25')
258. P53 protein expression, BRAF(V600E) mutation and their clinicopathologic significance in papillary thyroid carcinomas. **M.K. Shin**, J.W. Kim, S.K. Min, D.J. Lee, J.H. Kim, S.C. Lee, B.W. Chung, Y.S. Ju (Seoul, Republic of Korea) (20')
461. RFA in the local treatment of breast cancer. **M. Kontos** (Athens, Greece) (20')
441. Identification of *ZDHHC14* as a novel human tumour suppressor gene. **M. Yeste-Velasco**, X. Mao, R. Grose, S.C. Kudahetti, J. Marzec, N. Vasiljević, T. Chaplin, J.M. Foster, S. Karnam, A.-M. Chioni, D. Gould, A.T. Lorincz, T. Oliver, C. Chelala, G.M. Thomas, S. Mather, D. Berney, B.D. Young, Y.-J. Lu (London, UK; Philadelphia, PA, USA) (15')
540. Immune and environmental stimuli in non-Hodgkin lymphoma. M. Libra, **A. Garozzo**, F. Pezzino, G. Malaponte, S. Travali (Catania, Italy) (15')

## IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 15:30-17:30  
Thursday, October 9

Chair Persons: T. Grundström, S. Gerondakis, A. Weinhäusel

283. Regulation of diversification and affinity maturation of antibodies. J. Hauser, R. Kumar, A. Wallenius, C. Grundström, T. Ahmed, **T. Grundström** (Umeå, Sweden) (25')
316. Regulatory T cells require NF- $\kappa$ B to prevent autoimmune disease. N. Messina, T. Fulford, R. Grumont, P. Loh, L. O'Reilly, C. MacLean, R. Slattery, **S. Gerondakis** (Melbourne; Parkville, Australia) (20')
271. Immunoproteomics: Protein and peptide microarrays for defining serum-IgG signatures for cancer diagnostics. **A. Weinhäusel**, I. Gyurjan, J. Fuchs-Luna, R. Linhart, G. Wozniak-Knopp, F. Rüker, N. Pecha, R. Zeillinger, C. Rappaport, C. Singer, J. Söllner (Vienna, Austria) (20')
183. Regulation of cytotoxic lymphocyte function in health and disease. **I. Voskoboinik**, J.A. Lopez, M.R. Jenkins, J.A. Trapani (East Melbourne, Australia) (20')
104. A new method of endoscopic ultrasonography for determining lesion depth in gastric cancer. **A. Mitsunaga**, T. Tagata, T. Hamano, H. Teramoto, M. Kan, Y. Mitsunaga, M. Tobari, I. Shirato, M. Shirato, S. Yoshida, M. Shimada, T. Nishino (Yachiyo, Japan) (20')
146. Enhanced anti-tumor activity of erlotinib in combination with FAK tyrosine kinase inhibitors in non-small cell lung cancer. G.A. Howe, B. Xiao, H. Zhao, K.N. Al-Zahrani, M.S. Hasim, J. Villeneuve, H.S. Sekhon, G.D. Goss, L.A. Sabourin, J. Dimitroulakos, **C.L. Addison** (Ottawa, Canada) (15')

## CHEMOTHERAPY/PHARMACOLOGY

Room C, 18:00-20:00  
Thursday, October 9

Chair Persons: B.D. Przybyla, J.-F. Peyron, F.M. Aarestrup

155. Molecules involved in cross-talk between bone marrow and ablated tumor as potential markers for monitoring and predicting effectiveness of radio- and chemotherapies of solid tumors. **B.D. Przybyla** (Little Rock, AR, USA) (25')
110. Targeting leukemia metabolism or essential amino acid uptake shows anti-tumoral activity in PTEN-deficient T-cell mouse lymphomas and T-ALL/T-LL human cells. C. Rosilio, M. Nebout, V. Imbert, Z. Neffati, J. Benadiba, H. Endou, M.F. Wempe, **J.-F. Peyron** (Nice, France; Tokyo; Yokohama, Japan; Denver, CO, USA) (25')
206. Evaluation of the administration of atorvastatin and trans-Caryophyllenein in the prevention of side effects in Wistar rats undergoing chemotherapy with 5-FU. M.I.C. Campos, C.N. Campos, R. De P. do Nascimento, **F.M. Aarestrup**, B.J.V. Aarestrup (Juiz de Fora, Brazil) (20')
515. Advances in metastatic castration-resistant prostate cancer. **N. Kentepozidis** (Athens, Greece) (20')
517. Anti-cancer activity of aqueous and ethanol extracts from *Pyrus calleryana*. **F. Oliva**, I. Payan, M. Manzanares, W.F.A. Steelant, S. van Slambrouck (Miami Gardens, FL, USA) (15')
359. Prognostic value of p53 protein expression in bone marrow biopsies of patients with myelodysplastic syndromes that underwent bone marrow transplantation. **A. Pich**, L. Godio, M.G. Della Porta, E. Boveri (Turin; Pavia, Italy) (15')

## MOLECULAR MEDICINE

Room D, 09:00-11:00  
Thursday, October 9

Chair Persons: K. Ohlendieck, P. Diolez, B.L. Trigatti

107. Proteomic profiling of X-linked muscular dystrophy-associated cardiomyopathy. A. Holland, **K. Ohlendieck** (Maynooth, Ireland) (25')
264. Non-invasive integrative analysis of cardiac energetics, translation to human heart *in vivo*. **P. Diolez**, V. Deschodt-Arsac, L. Arsac, P. Dos Santos, P. Jais, M. Haissaguerre (Bordeaux, France) (25')
399. High-density lipoprotein signaling in macrophages and its role in atherosclerosis protection. **B.L. Trigatti** (Hamilton, Canada) (25')
209. Changes in the expression of incretin receptors in a mouse osteoblastic cell line in response to various glucose concentrations. **I. Watari**, E. Aoyama-Wakasugi, K.A. Podyma-Inoue, M. Yanagishita, T. Ono (Tokyo, Japan) (15')
269. X-linked centronuclear myopathy: Insights into Myotubularin MTM1 function from yeast. D.L. Bertazzi, L. Amosii, B. Rinaldi, J. Laporte, **S. Friant** (Strasbourg; Illkirch, France) (15')
296. Mitochondrial uncoupling in mice skeletal muscle in cancer cachexia. **N. Psychogios**, C. Constantinou, V. Righi, C.C. Fontes de Oliveira, A.A. Shestov, D. Mintzopoulos, S. Busquets, F.J. Lopez-Soriano, J. He, S. Milot, M.N. Mindrinos, F. Lepine, L.G. Rahme, J.M. Argilés, A.A. Tzika (Boston, MA; Cambridge, MA; Minneapolis, MN; Stanford, CA, USA; Barcelona, Spain; Laval, Canada) (15')

## MOLECULAR MEDICINE

Room D, 11:30-13:30  
Thursday, October 9

Chair Persons: I. Di Liegro, P.A. Ward, J. Russo

391. RNA-protein interactions in the nervous system of mammals. C.M. Di Liegro, P. Saladino, G. Schiera, P. Spies, D. Gyga, **I. Di Liegro** (Palermo, Italy; Muttenz, Switzerland) (20')
348. Role of histones in acute lung injury. **P.A. Ward**, F.S. Zetoune, J.J. Grailer, F. Fattahi (Ann Arbor, MI, USA) (20')
151. A review of the molecular mechanism on the effect of pregnancy in the prevention in breast cancer. **J. Russo**, J. Santucci Pereira, I.H. Russo (Philadelphia, PA, USA) (20')
189. The application of sequence analysis in the control for human infection with influenza A(H7N9) virus. **Y. Zhu**, X. Qi, L. Cui, C. Bao, K. Xu, J. Ai, H. Ji, A. Ge, F. Tang, M. Zhou (Nanjing, P.R. China) (15')
252. Mitofusin 2-tethering mitochondria and endoplasmic reticulum controls G0/G1-phase cell cycle arrest in vascular smooth muscle cells. D. Li, **X. Guo** (Wuhan, P.R. China) (15')
338. Altered copper homeostasis: An underestimated player in metabolic disorders. **M. Arciello**, A. Longo, C. Viscomi, G. Toietta, C. Balsano (Rome, Italy) (15')
280. Protein-ligand binding using spatial statistics and data mining techniques. **V. Rezaei**, H. Prez-Sa'nchez (Tehran, Iran; Murcia, Spain) (15')

## MOLECULAR MEDICINE

Room D, 15:30-17:30  
Thursday, October 9

Chair Persons: M.-N. Prioleau, N.A. Patel, Y. Yamada

467. Regulation of the spatiotemporal program of DNA replication in vertebrates. A.-L. Valton, F. Picard, J.-C. Cadoret, N. Boggetto, P. Alberti, C. Saintomé, J.-F. Riou, **M.-N. Prioleau** (Paris; Lyon, France) (20')
103. Alternative splicing of PKC $\delta$  during adipogenesis program provides clues for susceptibility to obesity. **N.A. Patel**, G. Carter, A. Apostolatos, R. Patel, D. Cooper, M. Murr (Tampa, FL, USA) (20')
102. Identification of chromosome 3q28 and *ALPK1* as susceptibility loci for chronic kidney disease in Japanese individuals. **Y. Yamada**, M. Oguri (Tsu; Nagoya, Japan) (20')
105. Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation. **M. Oguri**, Y. Yamada (Nagoya; Tsu, Japan) (20')
571. Necroptosis, a programmed cell death induced by TRAIL. S. Jouan-Lanhouet, O. Meurette, F. Le Cann, F. Faurez, S. Penna-Leverrier, M. Bonnet, O. Sergent, D. Lagadic-Gossmann, P. Vandenabeele, M.I. Arshad, M. Samson, **M.T. Dimanche-Boitrel** (Rennes; Lyon, France; Ghent, Belgium) (20')
613. Molecular mechanism of expression of MHC class I molecules. **K.S. Kobayashi** (College Station, TX, USA) (20')

## CARCINOGENESIS/MOLECULAR ONCOLOGY

Room D, 18:00-20:00  
Thursday, October 9

Chair Persons: N. Latruffe, A. Bhattacharyya

106. Red wine polyphenol extracts (RWPE) inhibit colon carcinoma cell proliferation *in vitro* and colonic pre-cancerous lesions *in vivo*. **N. Latruffe**, F. Mazué, D. Delmas, R.G. Mehta, N. Telang (Dijon, France; Chicago, IL; Montvale, NJ, USA) (25')
266. Role of Siah1 in *Helicobacter pylori*-infected gastric epithelial cancer cells. L. Das, S.B. Kokate, S. Rath, S.P. Singh, **A. Bhattacharyya** (Odisha, India) (25')
535. The prognostic and diagnostic significance of miR-155 levels in cancer from the side of cancer stem cells. **M. Ergüven** (Istanbul, Turkey) (25')
162. Functional analysis of human histone acetyltransferase (hMOF) in tumorigenesis. L.Cao, J. Su, D. Liu, L. Zhu, Y. Yang, D. Wu, L. Wang, J. Ding, F. Wang, Y. Cai, **J. Jin** (Jilin, P.R. China) (15')
156. SOCS-1-derived peptides protect against melanoma development in a syngeneic model. **J.A.B. Scutti**, F.M. Melo, F.V. Pereira, R. Berzagui, C.R. Figueiredo, A. Rabaça, E.G. Rodrigues, L.R. Travassos (São Paulo, Brazil) (15')
601. The role of the Bcl-2 family of apoptosis regulators in neoplastic transformation and early vertebrate development. **G. Gillet** (Lyon, France) (15')



## WORKSHOP: BIOMARKER DISCOVERY AND VALIDATION STRATEGIES

Room E, 09:00-11:00  
Thursday, October 9

Chair Persons: U. Manne, M. De Luca

- 499. Evidence-based cancer care requires development of patient population-specific molecular biomarkers. **U. Manne** (Birmingham, AL, USA) (30')
- 218. The cell surface heparan sulfate proteoglycan syndecans may serve as a possible molecular link between obesity and cancer risk. **M. De Luca** (Birmingham, AL, USA) (30')
- 247. Diet-related epigenetic biomarkers of cervical cancer risk. **C.J. Piyathilake** (Birmingham, AL, USA) (30')
- 366. Biomarker discovery and development in cancer: Biostatistical approaches. **S. Bae, K.P. Singh** (Birmingham, AL, USA) (30')

## GYNECOLOGICAL CANCER/THERAPEUTICS

Room E, 11.30-13.30  
Thursday, October 9

Chair Persons: N. Franken, J. Rudner

- 129. PARP1-inhibition sensitizes combined hyperthermia-radiation and combined hyperthermia-cisplatin treatment of cervical carcinoma cells. A. Oei, C. van Leeuwen, L. Stalpers, H. Rodermond, A. Bel, H. Crezee, P. Kok, **N. Franken** (Amsterdam, The Netherlands) (20')
- 139. Regulation of Mcl-1 stability: Impact on cancer cell survival and resistance radiotherapy. **J. Rudner** (Essen, Germany) (20')
- 562. Stem/progenitor cells in the human uterus: Implications for uterine tumors. **T. Maruyama** (Tokyo, Japan) (20')
- 115. Cell-cycle synchronization reverses Taxol resistance of human ovarian cancer cell lines. **X. Wang**, L. Pan, N. Mao, L. Sun, X. Qin, J. Yin (Beijing, P.R. China) (15')
- 284. FSH-TRPC3 interaction positively regulates the proliferation of ovarian cancer cells. X. Tao, H. Jin, Z. Zhang, R.C. Bast Jr, Y. Feng, **Y. Yu** (Shanghai, P.R. China; Houston, TX, USA) (15')
- 370. P53-governed regulation of PIK3CA expression in chemo-resistant ovarian cancer cells. S.M. Gaikwad, B. Thakur, **P. Ray** (Navi Mumbai, India) (15')
- 378. Network-based mining of genes associated with drug resistance in ovarian cancer. X. Liu, Y. Lu, J. Zhang, L. Li, **F. Yin** (Nanning, P.R. China) (15')

## DIAGNOSTICS/BIOMARKERS

Room E, 15:30-17:30  
Thursday October 9

Chair Persons: M. Libra, F. Hyodo

538. MMP-9 is a candidate marker of response to treatment with dabrafenib in melanoma cells. **S. Candido**, J.A. McCubrey, R. Salemi, F.M. Pezzino, G. Malaponte, M. Libra (Catania, Italy; Greenville, NC, USA) (15')
533. *In vivo* tumor redox imaging using magnetic resonance imaging. **F. Hyodo**, M.C. Krishna, J.B. Mitchell, H. Utsumi (Fukuoka; Tokyo, Japan; Bethesda, MD, USA) (15')
152. Mapping cell lineage growth in human tumors using somatic mitochondrial mutations. **P. Refinetti**, S. Morgenthaler, W.G. Thilly, P.O. Ekstrom (Lausanne, Switzerland; Boston, MA, USA; Oslo, Norway) (15')
233. Galectins in cancer: Jacks of all trades. **R. Heusschen**, I. Schulkens, J. Muller, A. Griffioen, Y. Beguin, V. Thijssen, J. Caers (Liège, Belgium; Amsterdam, The Netherlands) (15')
315. Development of a urine DNA test for liver cancer screening. **Y.-H. Su**, S. Jain, S. Chen, S.Y. Lin, W. Song (Doylestown, PA, USA) (15')
470. Diagnostic gene expression profile (GEP) for improving precision and molecular classification of hematological malignancies. **Y. Cohen**, O. Garach-Jehoshua, A. Bar-Chaim, O. Gutwein, A. Kornberg (Tel Aviv, Israel) (15')
135. Rapid method for detecting the KRAS oncogene from circulating tumor cells by using genechip based platform. **S.-R. Lin**, M.-Y. Huang (Ping-Tung; Kaohsiung, Taiwan, R.O.C.) (15')
363. The role of ERCC1 in predicting the prognosis and the treatment response in HNSCC - The implications of DNA repair involved in radiation therapy with DNA damage chemo-drugs. X. Ma, **J. Huang**, J. Zhang, L. Xue, L. Liu (Chengdu, P.R. China) (15')

## DIAGNOSTICS/BIOMARKERS

Room E, 18:00-20:00  
Thursday October 9

Chair Persons: K. Al-Nedawi, S. Demokan

349. Microvesicles in cancer: An intercellular communication mode and a source for biomarkers. **K. Al-Nedawi** (Hamilton, Canada) (20')
353. Saliva biomarkers as diagnostic tools in monitoring head and neck cancer. **S. Demokan** (Istanbul, Turkey) (20')
502. 'Old' prognostic factors for multiple myeloma (MM); Are they still valuable in the era of 'new' agents. **M.-C. Kyrtsonis** (Athens, Greece) (20')
322. Angiopoetin-like protein 2 is a potential biomarker for gastric cancer. **T. Yoshinaga**, T. Shigemitsu, H. Nishimata, A. Tomiyoshi, E. Hori, Y. Ozuno, S. Kiyoyama, K. Shiomori, T. Takei, M. Yoshida (Kagoshima; Miyakonojo, Japan) (15')
351. Metformin reduces the protein expression of multiple markers of drug resistance *in vitro* and *in vivo*. G.F. Davies, L. Lobanova, W. Dawicki, J. Gordon, T.G. Arnason, **T.A.A. Harkness** (Saskatoon, Canada) (15')
277. SELDI-TOF-MS: Screening the protein you are searching for. **X. Zeng**, B. Wang, Y. Ding, M. Tang, Y. Yang, H. Tao (Sichuan, P.R. China) (15')
360. High Serum MALAT1 expression is associated with poor prognosis in patients with gastric cancer. **H. Xia**, Q. Chen, F. Bi (Chengdu, P.R. China) (15')

## EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00  
Friday, October 10

Chair Persons: I. Herr, J.S. Deshane, J.A. Byrne

396. Innovative new treatment options for pancreatic cancer. **I. Herr** (Heidelberg, Germany) (25')
205. Targeting tryptophan metabolism for lung cancer. C.C. Schafer, Y. Wang, A. Sawant, T.H. Jin, S. Ponnazhagan, D. Zhi, S.C. Grant, **J.S. Deshane** (Birmingham, AL, USA) (25')
238. The target and the targeted - Tumor protein D52 (TPD52) and cancer. Y. Chen, N. Roslan, S. Frost, A. Kamili, L. Cantrill, **J.A. Byrne** (Westmead, Australia) (25')
141. Patched: a new target for the treatment of adrenocortical carcinoma. **I. Mus-Veteau**, L. Fiorini, E. Lalli (Valbonne, France) (25')
128. Therapeutic potential of mesenchymal stem cells in regenerative medicine. **N.B. Nardi** (Porto Alegre, Brazil) (20')

## THERAPEUTICS/TUMOR MICROENVIRONMENT

Room A, 11:30-13:30  
Friday, October 10

Chair Persons: L.F. Gibson, Y. Suzuki-Karasaki, J.A. McCubrey

358. Bone marrow microenvironment regulation of refractory leukemia. Y. Yang, A. Bruce, B. Moses, W. Slone, D. Pikte, J. Fortney, I. Martinez, K. Martin, S. Rellick, J. Simpkins, **L.F. Gibson** (Morgantown, WV, USA) (25')
153. Targeting mitochondrial fission/fusion dynamics: A novel approach for selective killing of cancer cells. **Y. Suzuki-Karasaki** (Tokyo, Japan) (25')
181. Suppressing prostate cancer by targeting NGAL. **J.A. McCubrey**, W.H. Chappell, S. Abrams, N. Davis, M. Libra, S. Candido, F. Nicoletti, J. Polesel, R. Talamini, R. Maestro, A.M. Martelli, M. Cervello, D. Maksimovic-Ivanic, S. Mijatovic, L.S. Steelman (Greenville, NC, USA; Catania; Aviano; Bologna; Palermo, Italy; Belgrade, Serbia) (25')
182. Inhibition of GSK-3 $\beta$  activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in breast cancer. **L.S. Steelman**, N.M. Davis, M. Sokolosky, S. Abrams, A.M. Martelli, F. Nicoletti, P. Fagone, C. Mazzarino, G. Malponte, M. Libra, M. Cervello, G. Montalto, D. Maksimovic-Ivanic, S. Mijatovic, K. Umezawa, J.A. McCubrey (Greenville, NC, USA; Bologna; Catania; Palermo, Italy; Belgrade, Serbia; Nagakute, Japan) (20')
563. FOXO3 tumor suppressor and out-FOXing cancer: Pathways to drug discovery. T. Hu, Y.M. Chung, S.-H. Park, J. Ma, J.S. Berek, **M.C.-T. Hu** (Stanford, CA, USA) (25')

## EXPERIMENTAL THERAPEUTICS

Room A, 15:30-17:30  
Friday, October 10

Chair Persons: S.M. Hyder, A. Provenzani, L. Buturovic

118. Therapeutic and preventive potential of nutraceutical luteolin against progestin-dependent breast cancer. M.T. Cook, Y. Liang, B. Mafuvadze, J. Zhang, S. Goyette, **S.M. Hyder** (Columbia, MO, USA) (25')
171. Novel insights about the NAMPT inhibitor FK866 mechanism of action in cancer cells. C. Zucal, V.G. D'Agostino, A. Casini, N. Thongon, T. Tebaldi, D. Soncini, I. Caffa, A. Ballestrero, A. Quattrone, A. Nencioni, **A. Provenzani** (Trento; Genoa, Italy) (25')
196. Personalized medicine in oncology: A critical assessment and a path forward. **L. Buturovic** (East Palo Alto, CA, USA) (25')
374. Effects of thermo-therapy on malignant mesothelioma. S. Nishikawa, A. Tanaka, K. Karasawa, J. Hyosun, K. Oida, **H. Matsuda** (Tokyo, Japan) (25')
142. Tumor biology and biophysics: A systems approach. **S.S. Knox** (Morgantown, WV, USA) (20')

## MOLECULAR ONCOLOGY

Room A, 18:00-20:00  
Friday, October 10

Chair Persons: D.E. Johnson, S.L. Bellis, R. Ketteler

203. Common genetic alterations in head and neck cancer: The impact of caspase-8 mutations. C. Li, A.M. Egloff, M. Sen, J.R. Grandis, **D.E. Johnson** (Pittsburgh, PA, USA) (30')
246. New tumor survival mechanisms mediated by the tumor glycome. M.J. Schultz, A.F. Swindall, C.N. Landen, W.E. Grizzle, D.J. Buchsbaum, **S.L. Bellis** (Birmingham, AL, USA) (30')
224. Targeting the autophagy machinery in cancer. N. Pengo, C. Luft, J. Freeman, K. Prak, J. Costa, J. Kriston-Vizi, **R. Ketteler** (London, UK) (30')
373. Modification of topoisomerases in mammospheres derived from breast cancer cell line: Clinical implications for combined treatments with tyrosine kinase inhibitors. **R. Peleg**, M. Romzova, I. Kogan-Zviagin, R.N. Apte, E. Priel (Beer Sheva, Israel) (30')

## HORMONES/MOLECULAR ONCOLOGY

Room B, 09:00-11:00  
Friday, October 10

Chair Persons: P.S. Rennie, D.G. Tang

158. A new class of estrogen receptor- $\alpha$  (ER $\alpha$ ) inhibitors to treat tamoxifen-resistant breast cancers. K. Singh, R.S.N. Munuganti, M. Butler, E. Leblanc, A. Cherkasov, **P.S. Rennie** (Vancouver, Canada) (25')
248. Prostate cancer stem cells and therapy resistance. **D.G. Tang** (Smithville, TX, USA) (25')
170. Mechanisms of regulation of vitamin D receptor expression by retinoids; implications for differentiation therapy of acute myeloid leukemia. A. Marchwicka, M. Cebrat, Ł. Śnieżewski, A. Łaskiewicz, G. Brown, **E. Marcinkowska** (Wroclaw, Poland; Birmingham, UK) (20')
340. Regulation of antitumor activity of estrogen receptor  $\beta$  through its phosphorylation. **Q. Ye**, B. Yuan, L. Cheng, R. Li (Beijing, P.R. China) (15')
606. Targeted therapies using siRNA-based gene silencing in cancer. **B. Ozpolat** (Houston, TX, USA) (15')
609. Histone deacetylase 5 blocks neuroblastoma cell differentiation by forming a protein complex with N-Myc and repressing target gene transcription. Y. Sun, P.Y. Liu, C.J. Scarlett, A. Malyukova, B. Liu, G.M. Marshall, K.L. MacKenzie, A.V. Biankin, **T. Liu** (Sydney; Ourimbah; Randwick; Bankstown; Liverpool, Australia) (10')
610. Biomarker development for sarcoma toward personalized medicine. **T. Kondo** (Tokyo, Japan) (10')

## SIGNALING

Room B, 11:30-13:30  
Friday, October 10

Chair Persons: W.L. Blalock, B.-M. Min, E.D. Arisan

217. Functional proteomics as a means to define signal transduction events in cancer. **W.L. Blalock**, M. Piazzini, M. Raffini, I. Faenza, A. Bavelloni (Bologna, Italy) (20')
251. Laminin-derived bioactive peptides: from molecular signaling to biomedical applications. I.-S. Yeo, S.-K. Min, H.K. Kang, S.Y. Jung, T.-K. Kwon, **B.-M. Min** (Seoul; Suwon, Republic of Korea) (20')
148. mTOR signalling alters cell fate following inhibition of cyclin-dependent kinases due to androgen receptor status in prostate cancer cells. **E.D. Arisan**, Ö. Berrak, P. Obakan, A. Çoker-Gürkan, N. Palavan Ünsal (Istanbul, Turkey) (20')
174. miR-612 suppresses the stemness of liver cancer via Wnt/ $\beta$ -catenin signalling. J. Tang, Z.-H. Tao, D. Wen, J.-L. Wan, D.-L. Liu, H.-C. Sun, J. Fan, **W.-Z. Wu** (Shanghai, P.R. China) (15')
289. A<sub>3</sub> adenosine receptor allosteric modulator induces an anti-cancer effect in liver cancer. **S. Cohen**, F. Barer, P. Fishman (Petach-Tikva, Israel) (15')
393. EGFR signaling in glioblastoma cells with a loss of *EGFR* gene copy and unusually mild clinical course of disease. **J. Skoda**, J. Neradil, K. Zitterbart, J. Sterba, R. Veselska (Brno, Czech Republic) (15')
516. Spatial organization directs selective signaling in cancer progression. I. Payan, S. McDonnell, W.F.A. Steelant, **S. van Slambrouck** (Miami Gardens, FL, USA; Dublin, Ireland) (15')

## DIAGNOSTICS/BIOMARKERS

Room B, 15:30-17:30  
Friday, October 10

Chair Persons: D. Delmas, A. Vral

433. The G2-micronucleus assay for the detection of *in vitro* chromosomal radiosensitivity in *BRCA1* and *BRCA2* mutation carriers. A. Baert, J. Depuydt, B. Poppe, T. van Maerken, F. Malfait, T. van Damme, K. De Leeneer, K. Claes, **A. Vral** (Ghent, Belgium) (15')
401. Phospholipids as potential biomarkers of hepatocellular carcinoma in cirrhotic patients. A. Cotte, E. Limagne, V. Cottet, S. Hamza, C. Binquet, S. Vinault, J.-M. Petit, A. Athias, J.-P. Pais de Barros, P. Hillon, **D. Delmas** (Dijon, France) (15')
369. N-REC/methotelin is an early diagnosis marker for Asbestos-related mesothelioma. **M. Imai**, O. Hino (Tokyo, Japan) (15')
400. Multiple drug resistance detection and biomarker reversal in companion canines. **T.G. Arnason**, L. Lobanova, G. Davies, C. Gaunt, V. MacDonald, T.A. Harkness (Saskatoon, Canada) (15')
450. Novel prognostic markers for uveal melanoma. **M. Mascolo**, S. Varricchio, R. Caltabiano, F. Tranfa, D. Strianese, G. Ilardi, D. Russo, G. De Rosa, S. Staibano (Naples; Catania, Italy) (15')
140. Exosomal shuttled microRNA: A new target for breast cancer therapy. **M. Yang**, J. Chen, B. Yu, F. Su, J.-D. Huang, E. Song (Guangzhou; Hong Kong, P.R. China) (15')
471. Cellular responses induced by IR play a role in cell fate decision. **M.Y. Kang**, E.Y. Jang, J.H. Kim, J.K. Kim (Jeongeup; Daejeon, Republic of Korea) (15')
493. Effects of analogues of 4,6,4'-trymethylangelicin on erythroid differentiation and NF- $\kappa$ B activity. **I. Lampronti**, G. Marzaro, A. Ferrarese, R. Milani, G. Montagner, V. Bezzerri, G. Cabrini, A. Chilin, R. Gambari (Ferrara; Verona, Italy) (15')

## MOLECULAR MEDICINE

Room B, 18:00-20:00  
Friday, October 10

Chair Persons: C.G. Sagerström, E. Isogai

136. Prep/Meis and Pbx cofactors poise promoters for activation by Hox proteins. F. Ladam, S.-K. Choe, **C.G. Sagerström** (Worcester, MA, USA) (20')
179. Prevention of enterohemorrhagic Escherichia coli O157:H7 infection by bacteria composed with intestinal flora. R. Suzuki, **E. Isogai**, H. Yoneyama, Y. Koyanagi, J. Nishimura, H. Isogai (Sendai; Hachinohe; Sapporo, Japan) (15')
178. Connective tissue growth factor and its receptor integrin  $\alpha$ v $\beta$ 3 in pathogenesis of hypertrophic scar. **X. Hu**, D. Hu, X. Fang, J. Shi, J. Liu (Xi'an, P.R. China) (15')
447. Contribution of the sphingolipid-associated mechanisms to the process of epithelial to mesenchymal transition. **A. Meshcheryakova**, M. Svoboda, E. Bajna, E. Jensen-Jarolim, H.C. Köfeler, D. Mechtcheriakova (Vienna; Graz, Austria) (15')
299. Aggressive growth and high malignancy of invasive micropapillary carcinoma of the extrahepatic bile duct. **T. Yoshizawa**, Y. Toyoki, H. Hirai, T. Haga, S. Sakuraba, K. Okano, Y. Wu, H. Seino, S. Morohashi, K. Hakamada, H. Kijima (Hiroaki, Japan) (15')
408. Nuclear localization of CD133 in sarcoma cells. **R. Veselska**, A. Nunukova, J. Skoda, J. Neradil, J. Jaros, M. Hermanova, I. Zambo, P. Mudry, K. Zitterbart, A. Hampl, J. Sterba (Brno, Czech Republic) (15')
550. Effects of bacteriocins on methicillin-resistant *Staphylococcus aureus* biofilm. **K.-I. Okuda**, S. Sugimoto, T. Iwase, A. Tajima, S. Yamada, Y. Mizunoe (Tokyo, Japan) (15')
602. First evidence that oligopyridines, alpha helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. C. Gloaguen, **A.S. Voisin-Chiret**, J. Sopkova-de Oliveira Santos, J. Fogha, F. Gautier, M. De Giorgi, G. Burzicki, S. Perato, C. Pétigny-Lechartier, K. Simonin-Le Jeune, E. Brotin, D. Goux, M. N'Diaye, B. Lambert, M.-H. Louis, P. Juin, R. Bureau, S. Rault, L. Poulain (Caen; Paris; Nantes, France) (10')

## EXPERIMENTAL THERAPEUTICS

Room C, 09:00-11:00

Friday, October 10

Chair Persons: W. Wang, M. Pajic

113. Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma. **W. Wang**, P. Lin, B. Sun, S. Zhang, W. Cai, C. Han, L. Li, H. Lu, X. Zhao (Tianjin, P.R. China; Houston, TX, USA) (20')
116. From functional genomics to precision medicine: Using well annotated models to define personalised treatment strategies for pancreatic cancer. A. Chou, V.T. Chin, A.M. Nagrial, A.J. Gill, P. Timpson, D.K. Chang, N. Waddell, J. Wu, S.M. Grimmond, A.V. Biankin, **M. Pajic** (Sydney; Brisbane, Australia) (15')
119. Inhibition of VEGFR-3 in hepatocellular carcinoma as a new strategy of treatment. A. Alam, **F. Dol-Gleizes**, I. Blanc, F. Gaujarengues, O. Bonnin, P. Barron, V. Martin, G. Lassalle, F. Bono (Toulouse, France) (15')
144. Role of Polycombs in sarcoma neoangiogenesis. **F. De Nigris**, T. Infante, A. Soricelli, C. Napoli (Naples, Italy) (15')
159. Identification of a tumor suppressor GIC-miRNA1 that targets the plasminogen activator system in glioblastoma-initiating cells. **T. Kondo** (Sapporo, Japan) (15')
365. Enhancing EGFR-targeted therapies in novel combination-based therapeutic approaches. G.D. Goss, **J. Dimitroulakos** (Ottawa, Canada) (15')
121. Anti-FGFR4 monoclonal antibody for the treatment of hepatocellular carcinoma. **C. Herbert**, G. Gueguen-Dorbes, C. Michaux, S. Saint Martin, G. Badet, A. Hubert, F. Dol, J.P. Herault, F. Blanche, B. Cameron, T. Dabdoubi, E. Remy, J.M. Herbert, F. Bono (Toulouse; Vitry/Seine, France) (15')
475. TIM-3 promotes HCC by regulating macrophages and T cells. W. Yan, X. Liu, H. Zhang, X. Liang, L. Gao, **C. Ma** (Jinan, P.R. China) (10')

## INFLAMMATION/DIFFERENTIATION

Room C, 11:30-13:30

Friday, October 10

Chair Persons: C. Yan, P. Swart, S.S. Signorelli

204. Stat3 downstream gene product chitinase 3-Like 1 is a biomarker of inflammation-induced lung cancer. **C. Yan**, L. Wu, M. Yu, P. Qu, X. Ding, H. Du (Indianapolis, IN, USA) (20')
198. Modulatory effects of *Salsola tuberculatiformis* Botch on UVB-induced inflammation in skin: Implications for skin cancer. T.U. Magcwebeba, A.C. Swart, **P. Swart** (Matieland, South Africa) (20')
335. Small molecules with unique anti-inflammatory effects for the prevention of colitis-associated cancer. **Q. Xu**, Y. Sun, Y. Shen, X. Wu, X. Wu, X. Wu, Q. Luo (Nanjing, P.R. China) (20')
445. New actors in chronic inflammation and fibrosis: The example of experimental kidney diseases. **J.-C. Dussaule**, C. Chatziantoniou (Paris, France) (15')
543. Peripheral arterial disease and inflammation. **S.S. Signorelli**, V. Fiore, G. Malaponte (Catania, Italy) (15')
278. Resveratrol inhibits NLRP3 inflammasome activation and mitigates progressive IgA nephropathy in mice. Y.-P. Chang, S.-M. Ka, W.-H. Hsu, A. Chen, **K.-F. Hua** (Ilan; Taipei, Taiwan, R.O.C.) (15')
191. Modulation of colitis-associated colon tumorigenesis in ICR mice by natural products. D.H. Kim, B. Sung, Y.J. Kang, J.Y. Jang, S.Y. Hwang, Y. Lee, M. Kim, H.Y. Chung, **N.D. Kim** (Busan, Republic of Korea) (15')

## BREAST CANCER

Room C, 15:30-17:30  
Friday, October 10

Chair Persons: A. Tanaka, P. Soucek

267. Role of nuclear factor- $\kappa$ B in both intrinsic and acquired resistance against endocrine therapy in breast cancer. K. Oida, H. Matsuda, **A. Tanaka** (Tokyo, Japan) (25')
274. Pharmacogenomics of breast carcinoma. **P. Soucek**, R. Vaclavikova, V. Brynychova, V. Hlavac, D. Vrana, V. Pecha, M. Trmkova, K. Kubackova, J. Gatek, I. Gut (Prague; Olomouc; Zlin, Czech Republic) (20')
231. Deeper insights into the deleterious role of ZNF217 in breast cancer. **P.A. Cohen**, J. Vendrell (Lyon, France) (15')
339. PES1 plays an essential role in human mammary tumor growth through regulation of the balance between ER $\alpha$  and ER $\beta$ . **L. Cheng**, J. Li, Q. Ye (Beijing, P.R. China) (15')
480. Natural aromatase inhibitors and their potential therapeutic effects on breast cancer. T.Y. Wong, F. Li, S.-M. Lin, S. Chow, W.-H. Cheung, F.L. Chan, S. Chen, **L.K. Leung** (Hong Kong, P.R. China; Chiayi, Taiwan, R.O.C.; Duarte, CA, USA) (15')
321. Loss of microRNA-27b-mediated gene repression promotes the generation of breast cancer stem cells. **R.-U. Takahashi**, H. Miyazak, T. Ochiya (Tokyo, Japan) (15')
130. MicroRNA regulation of radiotherapy sensitivity and resistance in breast cancer. H.E. Gee, D.A. Froio, L.S. Doculara, P.H. Graham, E.K.A. Millar, S.A. O'Toole, **T.J. Molloy** (Sydney, Australia) (15')

## BREAST CANCER/MOLECULAR ONCOLOGY

Room C, 18:00-20:00  
Friday, October 10

Chair Persons: I. Groisman, D. Dummer Meira

137. Translational control by 3'UTR binders during the breast cancer development. M.-L. Nairismägi, E.-M. Fuchtbauer, A. Vislovukh, N.N. Gralievskaya, B. Negrutskii, G. El'ska, Q. Meng, M. Petretich, E. Porto, G. Kratassiouk, C. Beldiman, R. Groisman, G. Pinna, A. Harel-Bellan, **I. Groisman** (Aarhus, Denmark; Kiev, Ukraine; Gif-Sur-Yvette, France) (25')
464. Molecular oncology: Challenges and perspectives. **D. Dummer Meira** (São Mateus, Brazil) (20')
125. Evaluation of neo-adjuvant chemotherapy responses in breast cancer patients using vascularization analysis. **W.-C. Shia**, D.-R. Chen (Changhua, Taiwan, R.O.C.) (15')
337. Difference in body mass index and insulin resistance according to the molecular subtype in a cohort of breast cancer patients. **M. Montella**, A. Crispo, G. Arpino, M. Giuliano, C. De Angelis, M. Grimaldi, E. Cavalcanti, F. Di Paola, I. Capasso, E. Esposito, M. D'Aiuto, G. D'Aiuto, F. Nocerino, G. Buono, G. Botti, M. De Laurentiis, S. De Placido (Naples, Italy) (15')
583. Cerebrospinal fluid interleukin-10 is associated with molecular subtype, tumor-associated macrophage infiltration and STAT3 activation in primary central nervous system diffuse large B-cell lymphoma. T. Mizowaki, **T. Sasayama**, K. Tanaka, K. Mizukawa, K. Takata, S. Nakamizo, H. Tanaka, H. Nagashima, M. Nishihara, T. Hirose, T. Itoh, E. Kohmura (Kobe, Japan) (15')
577. Autologous cytokine-induced killer cells with or without chemotherapy as first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial. **Y.-C. Xu**, Q. Xu, M. Ye, X.-F. Gu, X.-L. Lin, L. Sun, H.-M. Lu, H.-B. Fan, L. Tang, Y. Ma, Y.-R. Huang, H.-X. Wang (Shanghai, P.R. China) (15')
323. Critical requirement for the Tripartite motif protein 27 (TRIM27) in cancer development. **G. Zoumpoulidou**, C. Broceno, H. Li, D. Bird, G. Thomas, S. Mittnacht (London, UK; Barcelona, Spain; Portland, OR, USA) (15')



## HEMATOLOGICAL MALIGNANCIES/MOLECULAR ONCOLOGY

Room D, 09:00-11:00  
Friday, October 10

Chair Persons: M. Krstic-Demonacos, K. Piwocka

531. Determinants of drug and microenvironment response in acute lymphoblastic leukaemia. M. Qattan, D.W.-C. Chen, V. Saha, J.Z. Liu, L. Zeef, J.-M. Schwartz, E. Bakker, C. Demonacos, **M. Krstic-Demonacos** (Manchester; Salford, UK) (20')
456. BRCA1 translation in leukemia: Role of mRNA binding proteins. **K. Piwocka** (Warsaw, Poland) (20')
161. Genetic predisposition to acute myeloid leukemia and its specific chromosomal abnormalities. **K.N. Manola** (Athens, Greece) (20')
422. Pathogenesis of iron overload in myelodysplastic syndromes and the debate on iron chelation in low-risk MDS. **N. Shenoy**, A. Verma, Y. Ginzburg (New York, NY, USA) (15')
245. Role for protein phosphatase 2A in drug resistance in leukemia. **P.P. Ruvolo** (Houston, TX, USA) (15')
117. Cancerous inhibitor of PP2A as a novel regulatory protein of mitotic Plk1 in human cancer cells. **J.-S. Kim** (Seoul, Republic of Korea) (15')
376. FLAG-liposomal doxorubicin (Myocet) regimen for children with refractory or relapsed acute myeloid leukemia: A single centre experience. **F. Timeus**, P. Quarello, E. Barisone, E. Vassallo, F. Fagioli (Turin, Italy) (15')

## LUNG CANCER/BRAIN TUMORS

Room D, 11:30-13:00  
Friday, October 10

Chair Persons: Y.-H. Chen, J. He

317. Dual functions of claudin-7 in human lung cancer cell growth and metastasis. D.H. Kim, Z. Lu, Q. Lu, M. Shea, **Y.-H. Chen** (Greenville, NC, USA) (25')
145. Antitumor activity of cobrotoxin in human lung adenocarcinoma A549 cells and transplantation in nude mouse. **J. He**, Y. Xie, R. Han, Z. Qin (Suzhou, P.R. China) (25')
364. Molecular staging and personalized postoperative treatment of non-small cell lung cancer. **J. Zhang**, N. Chen, J. Qi, B. Zhou, X. Qiu (Shenyang, P.R. China) (25')
243. Protective effect of ulinastatin on hemorrhagic shock-induced acute lung injury. **T. Takahashi**, K. Inoue (Okayama; Takamatsu, Japan) (15')
474. TIM-4 controls cell proliferation, apoptosis and differentiation in NSCLC. Q. Zhang, H. Wang, X. Liang, C. Ma, **L. Gao** (Jinan, P.R. China) (15')
481. Bestinib, a novel Bcr-Abl inhibitor for Chronic Myeloid Leukemia, inhibits a wide array of Bcr-Abl mutants including imatinib-resistant T315I mutant. **P. Gupta**, K. Yang, F. Wang, X. Wang, R.J. Kathawala, L. Fu, Z.S. Chen (Queens, NY, USA; Guangzhou, P.R. China) (15')

## COLON CANCER

Room D, 15:30-17:30  
Friday, October 10

Chair Persons: N. Rivard, L. Corcos

114. Understanding the dual nature of SHP-2 in colorectal cancer. **N. Rivard**, G. Coulombe, J. Gagné-Sanfacon (Sherbrooke, Canada) (20')
134. Colon cancer progression: Combined analysis of gene expression, pre-mRNA splicing and genomic alterations. M. Pesson, A. Uguen, C.-H. Gattoliat, K. Trillet, P. De la Grange, M. Aubry, M. Robaszkiewicz, S. Redon-Quemener, G. Le Gac, A. Morel, B. Simon, **L. Corcos** (Brest; Paris; Angers; Rennes, France) (20')
568. Fbxw7 tumour suppressor gene: Cell fate control and signal integration in small intestine and colon. **A.S. Nateri** (Nottingham, UK) (20')
124. Relevance of MLH1 deficiency for reduced metastasis of colorectal cancer. I. Hinrichsen, B.P. Ernst, F. Nuber, S. Passmann, **A. Brieger** (Frankfurt, Germany) (15')
126. Significantly decreased the recurrence rate of colorectal cancer patients with Cetuximab treatment by using newly developed KRAS pathway associated molecules analysis Chip. **M.-Y. Huang**, S.-R. Lin (Kaohsiung; Ping-Tung, Taiwan, R.O.C.) (15')
486. Impact of genetics/epigenetics on colon cancer development and response to chemopreventive agents. **J.L. Williams**, P. Ji (Stony Brook, NY, USA) (15')
536. Essential role of cGMP/PKG signaling pathway in promoting proliferation and cell survival of human renal carcinoma cells. **Y. Ren**, X. Yao, G. Weng, S. Zhang, H. Qi (Ningbo, P.R. China) (15')

## COLON CANCER

Room D, 18:00-20:00  
Friday, October 10

Chair Persons: P. Demetter, M. Elmasry

253. Role of four-and-a-half LIM domains protein 2, a molecule interacting with ADAM-17, in colorectal cancer. **P. Demetter** (Brussels, Belgium) (20')
310. Management of advanced colorectal cancer, and the role of multidisciplinary team approach: A literature review, and a tertiary centre experience. **M. Elmasry**, T. Hore, A. Malik, M. Farag, S. Fenwick, H. Malik, G. Poston (Liverpool; Hertfordshire, UK) (20')
566. Obesity and colon cancer: What is the link? L. Nimri, E. Yehuda-Shneidman, **B. Schwartz** (Rehovot, Israel) (20')
262. DNA demethylation of nuclear factor-erythroid 2-related factor 2 promoter in 5-fluorouracil-resistant colorectal cancer cells. K.A. Kang, **J.W. Hyun** (Jeju, Republic of Korea) (15')
311. Increased expression of autophagy-related proteins in human colorectal cancer development, and correlation with DNA Microsatellite Stable and Unstable. P. Sena, **S. Mancini**, F. Mariani, M. Pedroni, G. Magnani, M. Benincasa, L. Roncucci (Modena, Italy) (15')
350. The densities of gastric endocrine cells tend to normalize following dietary guidance in patients with irritable bowel syndrome. **T. Mazzawi**, D. Gundersen, T. Hausken, M. El-Salhy (Stord; Bergen; Haugesund, Norway) (15')
525. Copy number variation sequencing for comprehensive diagnosis of chromosome disease syndromes. **D. Liang**, Y. Peng, W. Lv, G. Xu, D.S. Cram, L. Wu (Changsha; Beijing, P.R. China) (15')

BIOCHEMISTRY/MOLECULAR BIOLOGY

Room E, 09:00-11:00  
Friday, October 10

Chair Persons: P. Lombardi, P. Vodička, K. Umezawa

530. Recent advances in antitumour berberine. C. Geroni, C. Plasencia, C. Salvatore, **P. Lombardi** (Milan; Ancona, Italy; Barcelona, Spain) (15')
575. Molecular and functional characteristics of sporadic colorectal cancer. **P. Vodička**, L. Vodičková, J. Slyskova, B. Pardini, A. Naccarati, L. Bielik, V. Vymetálková, P. Procházka, M. Svoboda, M. Burocziova, P. Souček, S. Landi, R. Kumar, F. Canzian, A. Foersti, K. Hemminki (Prague; Pilsen, Czech Republic; Pisa; Turin, Italy; Heidelberg, Germany) (15')
160. Metabolite variation in colon cancer cell line HCT116 treated with antimicrobial peptide FF/CAP18. **K. Kuroda**, T. Fukuda, H. Isogai, K. Okumura, E. Isogai (Sendai; Hokkaido, Japan) (15')
291. Rac1 regulates skin tumors by regulation of keratin 17. M. Fu, **Z. Wang** (Xi'an, P.R. China) (15')
465. Nucleophosmin interacts with PinX1, which results in the reduction of the inhibitory effect of PinX1 on the telomerase activity. D.H.-C. Cheung, R. Jin, J.-J. Huang, **P.-C. Shaw** (Hong Kong; Beijing, P.R. China) (15')
202. Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility. **N. Yamamoto**, K. Shiraki, K. Sugimoto, Y. Inagaki, M. Tameda, Y. Takei, M. Ito, T. Nobori (Tsu, Japan) (15')
165. Inhibition of cancer cell invasion by bioactive metabolites. **K. Umezawa** (Nagakute, Japan) (15')
166. Suppression of cellular invasion by novel NF-kappa B inhibitor Exo-ene EQ in ovarian carcinoma cells. **K. Sidthipong**, K. Umezawa (Nagakute, Japan) (15')

SIGNALING/TUMOR BIOLOGY

Room E, 11:30-13:30  
Friday, October 10

Chair Persons: Q. Lu, A. Zaravinos

318. Inducible functional nonsense mutations of  $\delta$ -catenin promotes prostate tumorigenesis in mice overexpressing Myc oncogene and alters Wnt/ $\beta$ -catenin signaling. J. Nopparat, J. Zhang, Y.-H. Chen, Y. Zhu, C. Boykin, **Q. Lu** (Greenville, NC, USA) (15')
163. Novel miRNA profiles specific for renal cell carcinomas and upper tract urothelial carcinomas. **A. Zaravinos**, G.I. Lambrou, N. Mourmouras, P. Katafygiotis, G. Papagregoriou, K. Giannikou, D. Delakas, C. Deltas (Nicosia, Cyprus; Athens, Greece) (15')
168. The role of Wnt/ $\beta$ -catenin signaling in enterocyte turnover during methotrexate-induced intestinal mucositis in a rat. **I. Sukhotnik** (Haifa, Israel) (15')
285. The reversal of ABCG2-mediated multidrug resistance (MDR) by PD153035, an inhibitor of the epidermal growth factor receptor tyrosine kinase: An *in vitro* study. **G.-N. Zhang**, Y.-K. Zhang, R. Kathawala, Y.-J. Wang, C.R. Ashby Jr., Z.-S. Chen (Queens, NY, USA) (15')
324. SASH1 regulates melanocyte transepithelial migration through a novel Gas-SASH1-IQGAP1-E-Cadherin dependent pathway. **D. Zhou**, Z. Wei, S. Deng, T. Wang, M. Zai, H. Wang, L. Guo, J. Zhang, H. Zhong, L. He, Q. Xing (Chongqing; Shanghai, P.R. China) (15')
331. Nutlin-3 induces *BCL2A1* expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway. **S.-Y. Lee**, Y. Jeong, C. Sang-Sun Lee, H.-S. Kim (Seoul, Republic of Korea) (15')
173. MCPIP1 and clear cell renal cell carcinoma. J. Ligeza, N. Pochopien, K. Miekus, W. Wilk, J. Jaszczynski, A. Stelmach, J. Rys, **J. Jura** (Krakow, Poland) (15')
241. The significance of circulating endothelin-1 as a predictor of coronary artery disease status and clinical outcomes following coronary artery catheterization. **F. Mayyas**, M. Al-Jarrah, K. Ibrahim, D. Mfady, D.R. van Wagoner (Irbid, Jordan) (15')

## GYNECOLOGICAL CANCER/THERAPEUTICS

Room E, 15:30-17:30  
Friday, October 10

Chair Persons: M. Acevedo-Duncan, M.S. Ramayya

402. Effects of atypical PKC inhibitors on ovarian cancer proliferation and RNA levels. M. Shah, C. Apostolatos, H. Apostolatos, **M. Acevedo-Duncan** (Tampa, FL, USA) (15')
442. Human steroidogenic factor-1: Putative suppressor of epithelial ovarian cancer. **M.S. Ramayya**, M. Sheng, J. Davis, N. Makridakis, B.G. Rowan, K. Moroz (Honolulu, HI; New Orleans, LA, USA) (15')
314. Major dysfunctions in the endometrial response to ovarian steroids in endometriosis: A new possible link to inflammation and abnormal tissue growth. **A. Akoum**, N. Michaud, M. Al-Akoum (Québec, Canada) (15')
587. *In vivo* targeting of inflammatory cytokines in endometrial cancer: A new treatment option. A. Winship, M. van Sinderen, J. Donoghue, K. Rainczuk, **E. Dimitriadis** (Melbourne, Australia) (15')
379. Inhibition of cell growth and alterations of cell cycle by natural product SZ-NCI-0819 in ovarian cancer. **X. Liu**, S. Feng, F. Yin, Y. Lu, J. Zhang (Nanning; Shenzhen, P.R. China) (15')
237. Ovarian cancer markers for endometriosis: Is HE-4 superior to CA-125? **N.A. Bersinger**, B. McKinnon, M.D. Mueller (Berne, Switzerland) (15')
292. Experimental modeling of CRPC development and identification of novel CRPC-targeting therapeutics. **K. Rycaj**, Q. Li, B. Liu, X. Chen, D. Zhang, E. Jeong, A. Devkota, K. Dalby, D. Tang (Smithville, TX; Austin, TX, USA) (15')
548. Identification and enumeration of tumor spheres cultured from circulating epithelial tumor cells in patients with breast cancer. Is the number of mammospheres an indicator for metastatic disease? **M. Pizon**, D. Zimon, U. Pachmann, K. Pachmann (Bayreuth, Germany) (15')

## qPCR TECHNIQUES AND APPLICATIONS

Room E, 18:00-20:00  
Friday, October 10

Chair Persons: M. Capasso, G.M. Makrigiorgos, W.P. Kuo

190. Genome-wide association study to understand the genetics and biology of neuroblastoma. F. Cimmino, P. Pignataro, G. Acierno, A. Lasorsa, L. Pezone, M. Avitabile, A. Iolascon, **M. Capasso** (Naples, Italy) (30')
242. The PrimerBank resource of human and mouse PCR primer pairs for gene expression, detection and quantification. **A. Spandidos**, X. Wang, H. Wang, B. Seed (Boston, MA; St. Louis, MO, USA; Athens, Greece) (30')
259. COLD-PCR and digital COLD-PCR for ultra-sensitive detection of low-level resistance mutations in tumors and bio-fluids. **G.M. Makrigiorgos** (Boston, MA, USA) (30')
319. Identification of Oral Squamous cell Carcinoma salivary biomarkers from a genome-wide salivary microRNA expression profile. F. Momen-Heravi, A.J. Trachtenberg, Y.-S.L. Cheng, **W.P. Kuo** (Worcester, MA; Harvard, MA; Dallas, TX, USA) (30')

## PROSTATE CANCER

Room A, 09:00-11:00  
Saturday, October 11

Chair Persons: X. Mao, L. Sun

440. Population differences in the genetic risk of prostate cancer and predisposition loci in the Chinese population. **X. Mao**, J. Marzec, M. Li, Z. Zhang, N. Feng, X. Gou, Z. Sun, J. Xu, Y. Xue, A.A. Al Olama, X. Xu, J. Li, W. He, S. Benlloch, Z. Kote-Jarai, M. Wang, C. Chelala, The PRACTICAL Consortium, The CHIPGECS Group, D.F. Easton, R.A. Eeles, Y.-J. Lu, H. Zhang (London; Cambridge; Surrey, UK; Shanghai; Nanjing; Wuxi; Chongqing; Liaoning, P.R. China; Winston-Salem, NC, USA) (25')
519. Novel strategy for the treatment of metastatic, castrate resistant prostate cancer. F. Jernigan, Y. Wang, B. Zetter, **L. Sun** (Boston, MA, USA) (25')
506. TGF $\beta$  signaling and epithelial-to-mesenchymal transition in prostate cancer. **S.P.R. Shenoy**, A. Al-Azayzih, F. Gao (Athens, GA; Augusta, GA, USA) (25')
281. Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer. L. Chang, P.H. Graham, J. Hao, J. Ni, J. Bucci, P.J. Cozzi, J.H. Kearsley, **Y. Li** (Sydney; Kensington, Australia) (25')
438. Novel function of androgen receptor - The regulation of DNA replication and genomic movement. N.C. Bastus, X. Mao, B.D. Young, D. Sheer, **Y.-J. Lu** (London, UK) (20')

## BREAST CANCER

Room A, 11:30-13:30  
Saturday, October 11

Chair Persons: S.L. Kominsky, N.J. Plant

177. CITED2: a potential facilitator of breast cancer bone metastasis. S. Jayaraman, M. Doucet, **S.L. Kominsky** (Baltimore, MD, USA) (30')
194. Predicting the metabolic landscape of poor prognosis breast cancer. V. Leoncikas, H. Wu, L.T. Ward, A.M. Kierzek, **N.J. Plant** (Guildford; Alderley Park, UK) (30')
123. Mechanisms of field effects initiating carcinogenesis. **B. Czerniak** (Houston, TX, USA) (30')
565. Novel telomerase activators in aging and age-related diseases. **E. Priel**, E. Eitan, A. Tichon, I. Levi, R. Peleg, A. Gazit, S. Slavin (Beer-Sheva; Tel-Aviv, Israel) (30')

## EXPERIMENTAL THERAPEUTICS

Room A, 15:30-17:30  
Saturday, October 11

Chair Persons: C. Demonacos, C. Ropert, T. Nakamura

532. Tetratricopeptide Repeat (TPR) proteins: Potential role in cancer immunotherapy. M. Sadeq, M. Krstic-Demonacos, **C. Demonacos** (Manchester; Salford, UK) (25')
188. The yin and the yang of the use of TLR agonist in cancer therapy. A. Cruz, A.M. De Goes, **C. Ropert** (Belo Horizonte, Brazil) (20')
276. The p53-deficient lens tumors may recruit tumor-associated macrophages expressing IDO (indoleamine 2, 3-dioxygenase), which may be modulated by the Japanese herbal medicine (Kampo) Juzentaihoto in transgenic mice. **T. Nakamura** (Kurashiki, Japan) (20')
184. B cells and ectopic lymphoid structures at tumor site: Passengers, drivers and/or prognostic markers for clinical outcome? **D. Mechtcheriakova** (Vienna, Austria) (20')
553. Engineered stem cells expressing therapeutic genes caused the synergistic inhibitory effect via apoptotic pathway in a mouse model of breast cancer metastasis. **K.-C. Choi** (Cheongju, Republic of Korea) (20')
611. Preventive treatment of malignant cellular proliferations using a new method of immunogenetical therapy. **G. Glady** (Colmar, France) (15')

## TUMOR BIOLOGY/EPIGENETICS

Room A, 18:00-20:00  
Saturday, October 11

Chair Persons: S. Sarkar, J. Hashemi

295. Epigenetic changes in cancer cells and development of a combination therapy. **S. Sarkar** (Boston, MA, USA) (25')
459. Genetic and epigenetic mechanisms of small intestinal neuroendocrine tumors. **J. Hashemi**, O. Fotouhi, L. Sulaiman, M. Kjellman, A. Höög, J. Zedenius, C. Larsson (Stockholm, Sweden) (25')
458. Crossing the border: DNp73 in cancer metastasis. M. Steder, V. Alla, S. Emmrich, J. Vera, **B.M. Pützer** (Rostock, Germany) (25')
591. A physiological *in vivo* model for neuroectodermal child cancer. I. Hultman, **L. Ährlund-Richter** (Stockholm, Sweden) (25')
600. The Ras-ERK and Wnt/beta-catenin pathway interaction in tumorigenesis: Implications for the development of anti-cancer drugs. **K.-Y. Choi** (Seoul, Republic of Korea) (20')

## PROSTATE CANCER

Room B, 09:00-11:00  
Saturday, October 11

Chair Persons: W. Wagner, D. Pchejetski

101. Patients' satisfaction with different modalities of prostate cancer therapy - A retrospective survey among 634 patients. **W. Wagner** (Osnabrueck, Germany) (15')
120. Development of a new epigenetic-based blood test to stratify prostate cancer patients according to risk groups. H. Alshaker, C. Alifrangis, J. Mellor, J. Waxman, Y. Kawano, M. Eto, P. Jordan, A. Ramadass, A. Akoulitchev, M. Winkler, **D. Pchejetski** (London; Oxford; Norwich, UK; Amman, Jordan) (15')
175. Cytokines microenvironment deplete the pool of cancer stem cells to inhibit androgen independent prostate cancer. **W. Chen**, G. Wang, J. Guo, L.-A. Sun, H. Wang (Shanghai, P.R. China) (15')
197. The metabolism of adrenal  $11\beta$ -hydroxyandrostenedione - Novel pathways in prostate cancer. **A.C. Swart**, L.M. Bloem, L. Schloms, T. Du Toit, J. Quanson, E. Pretorius, R. Ehlers, P. Swart, D. Africander, K.-H. Storbeck (Stellenbosch, South Africa) (15')
227. Serum and urinary inter-alpha trypsin inhibitor peptides as biomarkers for prostate cancer. J.J. Jayapalan, K.L. Ng, A.H.A. Razack, **O.H. Hashim** (Kuala Lumpur, Malaysia) (15')
307. Efficiency of dispermidined-protoporphyrin IX mediated dynamic phototherapy on apoptosis of prostate cancer cells. C. Fidanzi, D.Y. Leger, L. Ghezali, Y. Limami, V. Sol, **B. Liagre** (Limoges, France) (15')
325. Association of genetic variants in estrogen receptor  $\alpha$  with the prostate cancer risk in Slovak population. **J. Jurečková**, M. Sivoňová-Kme'ová, E. Babušková, J. Kliment, D. Dobrota (Martin, Slovakia) (15')
608. A novel strategy of oncotherapy using a recombinant oncolytic measles virus. **C. Kai**, T. Sugiyama, T. Fujiyuki and M. Yoneda (Tokyo, Japan) (15')

## APOPTOSIS/PROSTATE CANCER

Room B, 11:30-13:30  
Saturday, October 11

Chair Persons: K. Fujita, T. Tatsuta

167. Galectin-9 induces apoptosis of HCC *in vitro* and *in vivo* through up-regulation of miR-1246. **K. Fujita**, T. Sakamoto, A. Morishita, T. Niki, H. Iwama, M. Hirashima, T. Masaki (Kagawa, Japan) (15')
309. A lectin which has both lectin and ribonuclease activity causes a cancer-selective induction of apoptosis. **T. Tatsuta**, S. Sugawara, K. Takahashi, M. Hosono (Sendai, Japan) (15')
345. Cell-penetrating TAT-BID fusion protein sensitizes cancer cells to apoptosis. **E.J. Orzechowska**, K. Staron, J. Trzcinska-Danielewicz (Warsaw, Poland) (15')
418. Differential sensitivity to apoptosome apparatus activation in non-small cell lung carcinoma and the lung. **E. Moravcikova**, E. Krepela, J. Prochazka, J. Cermak, K. Benkova (Prague, Czech Republic; Bern, Switzerland) (15')
419. Prostaglandin E1 protects against serum deprivation-induced bone marrow mesenchymal stem cell apoptosis by inhibition of endoplasmic reticulum stress. **K. Zeng**, B. Deng, L. Zhang, M. Wang, H. Jiang, M. Meng, P. Hua, Y. Yang (Guangdong, P.R. China; Linköping, Sweden) (15')
176. Two polysaccharide extracts from microalgae induce apoptosis in HepG2 cell line. X. Yu, **Z. Li**, R. Sumi (Beijing, P.R. China; Gifu, Japan) (15')
377. Aberrant signaling in heterogeneous prostate tumors concurs with disease progression. **S. Chevalier**, J. Rocha, F. Zouanat, T. Benidir, E. Scarlata, L. Hamel, F. Brimo, A. Aprikian (Montreal, Canada) (15')
439. Size-based isolation of circulating tumour cells and its application in advanced prostate cancer. L. Xu, A. Irrami, J. Shamash, **Y.-J. Lu** (London, UK) (15')

## PHARMACOLOGY/EXPERIMENTAL ONCOLOGY

Room B, 15:30-17:30  
Saturday, October 11

Chair Persons: K. Shiraki, R. Massoumi

180. The emerging role of Toll-like receptors in gastrointestinal cancers. **K. Shiraki** (Mie, Japan) (20')
468. The role of deubiquitination enzymes in liver fibrosis and cancer. R.R. Pannem, **K.C. Massoumi**, C. Dorn, C. Hellerbrand, **R. Massoumi** (Lund, Sweden; Regensburg, Germany) (20')
342. Nanosecond pulsed electric fields (nsPEFs) - Modifications and anticancer applications - *In vitro* study. **J. Kulbacka**, J. Saczko, M. Kotulska, A. Choromańska, N. Rembiałkowska, P. Surowiak, M. Dubińska-Magiera (Wrocław, Poland) (20')
219. Alkylphosphocholines and the Current Anticancer Profile of Erufosine. **F. Kaleağasıoğlu**, M.R. Berger (Istanbul, Turkey; Heidelberg, Germany) (20')
225. Reversal effects of tetramethylpyrazine on multidrug resistance in hepatocellular carcinoma cells BEL-7402/ADM by inhibiting calcium pathway. **X. Wang**, H. Li, M. Liu, Y. Liu, L. Ouyang (Shiyan, P.R. China) (15')
518. Investigating metal aberrations in cancer: From basic science to therapeutic enquiry. S. Masaldan, D. Denoyer, **M. Cater** (Burwood; Parkville, Australia) (15')
607. Single nucleotide polymorphism (SNP) profile, circulating plasma proteins and cytokines in head and neck squamous cell carcinoma (HNSCC) as biomarkers for cancer risk and clinical outcome. **N. Laytragoon-Lewin**, L. Cederblad, M. Olin, B.Å. Andersson, M. Nilsson, L.E. Rutqvist, J. Lundgren, S. Löfgren and F. Lewin (Jönköping, Sweden) (10')

## TUMOR BIOLOGY

Room B, 18:00-20:00  
Saturday, October 11

Chair Persons: Z. Pei, S.P.R. Shenoy

293. Microbial link to esophageal adenocarcinoma. L. Yang, **Z. Pei** (New York, NY, USA) (25')
507. Mechanisms regulating Akt-mediated endothelial-barrier function. **S.P.R. Shenoy**, F. Gao, A. Al-Azayzih (Athens, GA; Augusta, GA, USA) (20')
423. Interaction of epigenetics and TGF beta pathway in renal cell carcinoma - A potential therapeutic target with hypomethylating agents. **N. Shenoy**, T. Bhagat, A. Verma (New York, NY, USA) (15')
294. HIV-induced immunosuppression is associated with colonization by plant pathogens in the gut. **L. Yang**, M.A. Poles, G.S. Fisch, Y. Ma, C. Nossa, R.G. Norman, J.A. Phelan, Z. Pei (New York, NY; Houston, TX, USA) (15')
298. Using chemical proteomics and feeding RNAi to identify target of bioactive small molecular compound. B. Han, L.-Y. Huang, Z.-J. Yao, **L.-S. Wang** (Shanghai, P.R. China) (15')
308. Plasma membrane translocation of REDD1 governed by GPCRs contributes to mTORC1 activation. G. Michel, H.W.D. Matthes, M. Hachet-Haas, K. El Baghdadi, J. De Mey, R. Pepperkok, J.C. Simpson, J.-L. Galzi, **S. Lecat** (Illkirch, France; Heidelberg, Germany; Dublin, Ireland) (15')
537. DSS1 as a potential prognostic marker for breast cancer progression and relapse-free patient survival. **A. Rezano**, K. Kuwahara, M. Yamamoto-Ibusuki, M. Kitabatake, P. Moolthiya, S. Phimsen, T. Suda, S. Tone, Y. Yamamoto, H. Iwase, N. Sakaguchi (Bandung, Indonesia; Kumamoto; Kurashiki, Japan) (15')



## MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 09:00-11:00  
Saturday, October 11

Chair Persons: G. Luo, S. Liekens

526. Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China. **G. Luo**, Z. Xiao, Z. Liu, J. Long, X. Yu (Shanghai, P.R. China) (30')
460. Aminocarboxymethylthiophenes (ACT) as potent and selective anti-cancer agents. A. Jejcic, J. Thomas, R. Romagnoli, W. Dehaen, J. Balzarini, **S. Liekens** (Leuven, Belgium; Ferrara, Italy) (15')
282. The mechanism research of bioactive peptide synergistic chemotherapy on the gastric cancer cells. **X. Su**, L. Yu, C. Dong, J. Zhang, Y. Su, H. Cui, W. Han (Hohhot, P.R. China) (15')
327. CD44-targeted chemotherapy inhibits tumor recurrence in head and neck squamous cell carcinoma. **N. Umemura**, E. Ohkoshi, H. Sakagami (Sakado, Japan) (15')
330. Schizophrenia and cancer: The key role of microRNAs as biomarkers in cancer, schizophrenia and other CNS disorders. **E. Rizos**, N. Siafakas, E. Katsantoni, V. Zoumpourlis (Athens, Greece) (15')
361. Effects of 5-azacytidine on tumour cell interactions with the immune system. **M. Reiniš**, V. Vlková, M. Indrová, R. Mikyšková, V. Hrušková, J. Bieblová, J. Šímová (Prague, Czech Republic) (15')
362. IFN- $\gamma$ -induced DNA demethylation of antigen presenting machinery genes in MHC class I-deficient tumour cells. **V. Vlková**, I. Štěpánek, V. Hrušková, F. Šenig, J. Šímová, J. Bieblová, M. Indrová, M. Reiniš (Prague, Czech Republic) (15')

## CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:30  
Saturday, October 11

Chair Persons: A. Semczuk, J. Saczko

576. Role of clinico-prognostical features in patients affected by uterine carcinosarcomas. **A. Semczuk**, M. Gogacz, K. Cieplinski, A. Pyra, Ł. Nowakowski, P. Olcha, T. Rechberger (Lublin; Nowa Dęba, Poland) (15')
341. Metastatic cancers treated by electrochemotherapy with cisplatin and Betulinic acid - *In vitro* study. **J. Saczko**, J. Piłat, J. Bar, A. Choromańska, N. Rembiałkowska, A. Kuzan, I. Kamińska, M. Kotulska, M. Drag-Zalesińska, J. Kulbacka (Wrocław, Poland) (15')
199. Anatomic liver resection of segment 6, 7 and 8 is an alternative modality for maximal hepatectomy in the treatment of hepatocellular carcinoma. **C. Jia**, Q. Yang, J. Weng, Y. Chen, Y. Fu (Hainan, P.R. China) (15')
220. Venous versus arterial thrombosis in cancer: the role of antithrombotic prophylaxis. **E. Gavrilaki** (Thessaloniki, Greece) (15')
186. A kind of PSA management software can be used for clinical and application. **Z. Song**, T. Zheng, W. Dong, H. Su, W. Liui, N. Lei (Sichuan, P.R. China) (15')
187. Inhibition of VEGF agents therapy with or without docetaxel as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. N. Lei, **Z. Song** (Sichuan, P.R. China) (15')
372. Establishment and characteristics of clinically relevant cancer cells which are resistant to conventional fractionated radiotherapy. Y. Kuwahara, T. Shimura, M. Suzuki, M. Fukumoto, S. Takahashi, **M. Fukumoto** (Sendai, Japan) (15')
421. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance. H. Zhao, L. Zheng, X. Li, **L. Wang** (Hangzhou, P.R. China) (15')

## INFECTIOUS DISEASES/MOLECULAR MEDICINE

Room C, 15:30-17:30  
Saturday, October 11

Chair Persons: G. Sourvinos, I.N. Mammias, K.M. Antoniou

509. Insights into the elusive human papillomavirus E5 oncogene. C. Wasson, M. Muller, E. Prescott, S. Roberts, **A. MacDonald** (Leeds; Birmingham, UK) (20')
272. Detection and prognostic role of HPV in head and neck carcinoma. **C. Lo Nigro**, D. Vivenza, M. Monteverde, M. Fortunato, N. Denaro, L. Lattanzio, F. Tonissi, A. Ghiglia, E. Russi, M.C. Merlano (Cuneo, Italy) (15')
446. CD4 receptor down-modulators as anti-HIV drugs. **K. Vermeire**, V. van Puyenbroeck, T.W. Bell (Leuven, Belgium; Reno, NV, USA) (15')
451. MicroRNA-21 is significantly overexpressed in Merkel cell polyomavirus-positive non-small cell lung cancer. **I. Lasithiotaki**, K.M. Antoniou, E. Tsitoura, A. Koutsopoulos, E. Lagoudaki, D.A. Spandidos, N.M. Sifakas, G. Sourvinos (Heraklion, Greece) (15')
452. Human papillomaviruses in childhood: A brief overview. **I.N. Mammias**, G. Sourvinos, D.A. Spandidos (Heraklion, Greece) (15')
501. Decreased MicroRNA29a expression in Idiopathic Pulmonary Fibrosis (IPF) is associated with Collagen type 1a1 expression and eosinophilia in Bronchoalveolar Lavage Fluid (BALF). E. Tsitoura, A.U. Wells, K. Karagiannis, I. Lasithiotaki, S. Sarantoulaki, H. Sato, D.A. Spandidos, N.M. Sifakas, G. Sourvinos, **K.M. Antoniou** (Heraklion, Greece; London, UK) (15')
588. O<sub>2</sub>-reductase activity of Trypanothione reductase from *Leishmania infantum*. **F. Malatesta** (Rome, Italy) (15')
572. Applications of epigenetics in forensic sciences. **R. Dumache**, C. Muresan, A. Enache (Timisoara, Romania) (10')

## INFECTIOUS DISEASES

Room C, 18:00-20:00  
Saturday, October 11

Chair Persons: A. MacDonald, A. Basu, S. Sifakis

406. Host pathogen interaction in Japanese encephalitis virus infection: From bench to bedside. **A. Basu** (Manesar, India) (20')
510. Merkel cell polyomavirus - The new kid on the tumour virus block. H. Abdul-Sada, L. Knight, D. Griffiths, A. Whitehouse, **A. MacDonald** (Leeds, UK) (15')
586. Novel findings in NAFLD and HCV-related steatosis. **C. Balsano** (Rome, Italy) (20')
598. Human papillomavirus and other biomarkers in tonsillar and base of tongue cancer, and their influence on response to treatment. A. Näsman, C. Nordfors, N. Tertipis, N. Grün, J. Du, L. Haeggbloom, L. Sivars, A. Ährlund-Richter, A. Vlastos, D. Lindquist, T. Ramqvist, E. Munck-Wikland, **T. Dalianis** (Stockholm, Sweden) (15')
529. Cell-free fetal DNA in non-invasive prenatal diagnosis and the prediction of preeclampsia. **S. Sifakis**, A. Zaravinos, N. Maiz, D. Kappou, Z. Koukou, K. Nicolaidis, D.A. Spandidos (Heraklion, Greece; London, UK) (10')
569. Detection of pleural plaques in workers exposed to inhalation of natural fluoro-edenite fibres. **V. Rapisarda**, L. Proietti, V. Ricceri, A. Musumeci, A. Marconi, L. Fago, M. Libra, M. Ferrante, F. Caranna, C. Ledda (Catania; Messina, Italy) (10')
200. Human papillomavirus type 16 promotes cervical cancer severity. **M. Ponglikitmongkol**, P. Wanichwatanadecha, W. Umnajvjit, J. Ngamkham, S. Sirisrimangkorn, J. Kaewprag (Bangkok, Thailand) (15')
255. IGF expression in HPV-related and HPV-unrelated human cancer cells. **J. Durzyńska**, E. Barton (Poznań, Poland; Philadelphia, PA, USA) (15')

## BRAIN TUMORS

Room D, 09:00-11:00  
Saturday, October 11

Chair Persons: H. Castel, L. Oliver, E. Sen

332. Signaling switch of a vasoactive peptide GPCR: Prototypic chemotaxic mechanism involved in glioma. V. Le Joncour, C. Lecointre, P.-O. Guichet, N. Perzo, L. Desrues, J.E. Joubert, R. Modzelewski, P. Véra, P. Bohn, F. Morin, P. Gandolfo, **H. Castel** (Mont-Saint-Aignan; Rouen, France) (20')
580. Characterization of the interaction between mesenchymal stem cells and tumoral cells using the Glioma model. **L. Oliver**, C. Pecqueur, C. Chauvin, F.M. Vallette (Nantes; St Herblain, France) (20')
407. Targeting oxidative stress in glioblastoma: Implications in therapy. **E. Sen** (Manesar, India) (20')
328. Modelling of JNK network dynamics as a novel prognostic indicator in Neuroblastoma. D. Fey, W. Kolch, B.N. Kholodenko, **D.R. Croucher** (Dublin, Ireland; Sydney, Australia) (15')
375. Glutaminase-mediated metabolic pathway involves glioblastoma resistance to mTOR-targeted therapies. **K. Tanaka**, T. Sasayama, Y. Irino, K. Takata, H. Nagashima, K. Masui, B. Gini, H. Yang, P.S. Mischel, E. Kohmura (Kobe, Japan; La Jolla, CA, USA) (15')
254. Identification of *OLIG2* as most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. **A.-L. Trépant**, C. Bouchart, S. Rorive, S. Sauvage, C. Decaestecker, P. Demetter, I. Salmon (Brussels; Gosselies, Belgium) (15')
195. HtrA proteins as possible targets in cancer therapy. M. Jarzab, T. Wenta, P. Glaza, D. Zurawa-Janicka, A. Polit, J. Ciarkowski, **B. Lipinska** (Gdansk; Krakow, Poland) (15')

## THERAPEUTICS/BREAST CANCER

Room D, 11:30-13:30  
Saturday, October 11

Chair Persons: G. Massillon-JL, H. Kijima, R. Lupu

300. Overview of the absorbed dose received by patients during radiotherapy for cancer treatment. **G. Massillon-JL** (México) (25')
462. Clock gene product DEC, as a bHLH transcription factor, negatively regulates angiogenesis factors VEGF. **H. Kijima**, Y. Wu, T. Yoshizawa, T. Suzuki, S. Goto, H. Hirai, T. Haga, H. Seino, S. Morohashi (Hirosaki, Japan) (20')
482. Small-molecule Fatty Acid Synthase (FASN) inhibitors promote inhibition of tumor growth and induce apoptosis of breast cancer. **R. Lupu**, T. Heuer, G. Kemble, S. Kaufmann (Rochester, MN; Menlo Park, CA, USA) (25')
228. Localization of the stem cell markers LRG5 and Nanog and the oncogenic c-kit suggests a new approach to the treatment of pancreatic cancer. **A. Amsterdam** (Rehovot, Israel) (20')
405. Tumor-specific gene therapy systems mediated by tumor-targeting Salmonella: Construction, validation and application. **Z. Hua**, J. Chen, X. Cheng, G. Chen, X. Zhang, L. Jia, D. Wei, J. Ye, W. Jiang (Nanjing, P.R. China) (15')
437. Expression and functionality of a histone H2A variant in the mammary epithelium. F. Monteiro, H. Laranjeira, C. Cotrim, C. Jerónimo, **L. Helguero** (Aveiro; Porto, Portugal) (15')

## NERVOUS SYSTEM TUMORS

Room D, 15:30-17:30  
Saturday, October 11

Chair Persons: I. Horwacik, T. Eckschlager, H.M. Said

297. Contradictory effects of valproate on neuroblastoma cells. K.M. Ashraf, J. Hraběta, T. Groh, M. Stiborova, **T. Eckschlager** (Prague, Czech Republic) (25')
303. Targeting GD2 ganglioside and aurora A signaling pathways in neuroblastoma - *In vitro* studies. **I. Horwacik**, M. Durbas, E. Boratyn, H. Rokita (Kraków, Poland) (25')
443. Inhibitory targeting of CA9 by two different sulfonamide derivative compounds including acetazolamide in human brain cancer. **H.M. Said**, C. Hagemann, F. Carta, A. Katzer, A. Scozzafava, M. Flentje, C.T. Supuran (Würzburg, Germany; Firenze, Italy) (25')
268. Molecular studies on the anti-tumor effects of tryptanthrin on human neuroblastoma cells. **K.-N. Leung**, X. Liao (Hong Kong, P.R. China) (15')
273. Antitumor peptides derived of human Lactoferricin as cancer therapy targeting the membrane lipid phosphatidylserine exposed by malignant melanoma and glioblastoma. S. Riedl, B. Rinner, H. Schaidler, M. Asslaber, K. Lohner, **D. Zweytlak** (Graz, Austria; Queensland, Australia) (15')
301. Gene expression and function based identification of biomarkers for diagnosis of glioma malignancies. **P. Vaitkienė**, D. Skiriutė, G. Steponaitis, K. Skauminas, A. Kazlauskas (Kaunas, Lithuania) (15')

## MOLECULAR MEDICINE

Room D, 18:00-20:00  
Saturday, October 11

Chair Persons: J. Hogan, M.H. Borawska

597. Prostaglandin D2 synthase is a novel and independent prognostic biomarker in stage two colorectal cancer. **J. Hogan**, C. Judge, C. Dowling, S. Shebally, D. Healy, K. Culligan, P. Kiely, T. Dalton, R. Gupta, M. Kalady, J.C. Coffey (Limerick, Ireland; Cleveland, OH, USA) (25')
389. The interaction of bee bread and Royal Jelly with temozolomide in human *Glioblastoma multiforme* (U87MG) and normal human astroglia (SVGp12) cell lines. **M.H. Borawska**, E. Bartosiuk, S.K. Naliwajko, R. Markiewicz-Zukowska, J. Moskwa (Białystok, Poland) (20')
368. Effect of *Radix Scutellariae* extract on the prevention and treatment of disuse-induced osteoporosis and the impact according to gender. **C. Li**, G. Zhang, Y. Niu, Q. Mei (Xi'an, P.R. China) (15')
371. Introduction to brain-computer interfaces and the discriminant space self-organizing map. **A. Onishi**, K. Natsume (Fukuoka, Japan) (15')
390. Propolis as an anti-proliferative and anti-metastatic agent in human *Glioblastoma multiforme* (U87MG) and diffuse astrocytoma stem-like cell lines. **S.K. Naliwajko**, R. Markiewicz-Zukowska, J. Moskwa, Z. Mariak, M.H. Borawska (Białystok, Poland) (15')
492. Development of a transgenic mouse line carrying a functional human  $\beta$ -globin gene with the IVSI-6 thalassemia mutation for *in vivo* screening and validation of aberrant splicing correctors. **A. Finotti**, G. Breveglieri, J. Gasparello, N. Bianchi, I. Lampronti, F. Salvatori, E. Fabbri, C. Zuccato, L.C. Cosenza, G. Montagner, M. Borgatti, M. Rubini, V. Aiello, R. Gambari (Ferrara, Italy) (10')
388. Cardiopulmonary bypass with iloprost in heparin-induced thrombocytopenia (HIT) patients. **E. Melissari**, G. Soufla (Athens, Greece) (10')
290. Molecular aspects/genetic predisposition to Heparin induced Thrombocytopenia (HIT/T syndrome). **G. Soufla**, E. Iliopoulou, A. Angelidis, M. Katafygioti, N. Matoula, E. Melissari (Athens; Heraklion, Greece) (10')

## MOLECULAR ONCOLOGY/CANCER PREVENTION

Room E, 09:00-11:00  
Saturday, October 11

Chair Persons: M.F.A. Farag, V. Jurisic, S.-C. Tang

305. Can aspirin and cancer prevention be ageless companions? **M.F.A. Farag**, T. Janjua, M. Elmasry, M. Butt (Stevenage; Hull; Liverpool, UK) (20')
594. Novel agents in the hormonal therapy of breast cancer. **S.-C. Tang** (Augusta, GA, USA) (20')
154. Influence of cytokines on expression of cell surface molecule in tumor cells. **V. Jurisic**, T. Srdic-Rajic, G. Konjevic (Belgrade, Serbia) (20')
347. Incomplete segregation of MSH6 mutations with phenotype of Lynch syndrome. **F. Duraturo**, R. Liccardo, A. Cavallo, M. De Rosa, G.B. Rossi, P. Izzo (Naples, Italy) (15')
417. Proton beam and X irradiation influence motility properties of tumor cells. **K.A. Jasińska**, A. Borkowska, P. Koczurkiewicz, M. Michalik, P. Olko, B. Romanowska-Dixon, M. Elas, K. Urbańska, Z. Madeja (Kraków, Poland) (15')
420. Distribution of vemurafenib, a personalized medicine compound, in malignant melanoma tissue analyzed by MALDI mass spectrometry imaging. **Y. Sugihara**, Á. Végvári, C. Welinder, T. Fehniger, G. Marko-Varga (Lund, Sweden; Tokyo, Japan) (15')
496. TIPE1 induces cell death in hepatocellular carcinoma cells. **X. Liang**, Z. Zhang, L. Gao, H. Ma, X. Liu, Y. Pan, W. Yan, H. Shan, Y.H. Chen, C. Ma (Jinan, P.R. China; Philadelphia, PA, USA) (15')

## MOLECULAR MEDICINE/ONCOLOGY

Room E, 11:30-13:30  
Saturday, October 11

Chair Persons: N. Telang, C. Prigent, W.G. Jiang

143. Preventive efficacy of the non-steroidal anti-inflammatory drug Sulindac on cell culture models for genetically predisposed early onset colon cancer. **N. Telang** (Montvale, NJ, USA) (15')
596. Aurora - A kinase activity and cancer. **C. Prigent** (Rennes, France) (20')
122. Novel approaches in the management of transcoelomic spread of cancers. **W.G. Jiang** (Cardiff, UK) (15')
551. Atmospheric scanning electron microscopy (ASEM) of axonal segmentation in neurons and phagocytosis of dendritic cells. **C. Sato** (Tsukuba, Japan) (20')
549. Fine structures of biofilms in solution visualized by atmospheric scanning electron microscopy. **S. Sugimoto**, K.-I. Okuda, M. Sato, C. Sato, Y. Mizunoe (Tokyo; Tsukuba, Japan) (10')
132. A novel isoform of MLL5 as a potential therapeutic target for HPV-associated cervical cancer. D.S. Nin, C.W. Yew, W. Huang, **L.-W. Deng** (Singapore) (15')
589. Complete pathological response following neoadjuvant chemotherapy in early breast cancer, a retrospective study. **T. Janjua**, D. Ramanujam, I. Mausam, W. Ali, M. Butt (Cottingham, UK) (15')
487. LncRNA-microRNA interactions as a new strategy in designing diagnostic and/or therapeutic tools in cancers: Focus on SOX2OT in ESCC. **M. Shafiee** (Gorgan, Iran) (10')

## MOLECULAR ONCOLOGY

Room E, 15:30-17:30  
Saturday, October 11

Chair Persons: V. Zoumpourlis, T. Koufakis

381. The ideological frame of the determination of the genetic basis of cancer. **V. Zoumpourlis**, E. Skourti (Athens, Greece) (10')
112. Hunting the gene: Analysis and meta-analysis of genetic association studies in oncology. **T. Koufakis** (Larissa, Greece) (15')
483. Particularities of maspin and mena expression in intestinal-type and diffuse gastric carcinoma. **S. Gurzu**, H. Sugimura, J. Orłowska, Z. Kadar, T. Bara Jr, I. Jung (Tirgu-Mures, Romania; Hamamatsu, Japan; Warsaw, Poland) (15')
484. Rare variants of gastric carcinoma: An update. I. Jung, T. Bara, H. Sugimura, Z. Szentirmay, S. Turdean, O. Serester, **S. Gurzu** (Tirgu-Mures, Romania; Hamamatsu, Japan; Budapest, Hungary) (15')
498. The combinatory effects of PPAR-gamma agonist and Survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells. **Y. Wang**, H. Tan, D. Xu, A. Ma, L. Zhang, J. Sun, Z. Yang, Y. Liu, G. Shi (Shanghai; Qingdao, P.R. China) (15')
523. Expression profile of the DLC protein family in hepatocellular carcinoma. **D. Wolosz**, G. Szparecki, E. Wilczek, B. Gornicka (Warsaw, Poland) (15')
564. Optical molecular imaging: A review of recent progression and applications in oncology. K. Wang, Y. Du, **E. Li**, J. Tian (Beijing, P.R. China) (15')
599. The unexpected journey of MSCs in tumor microenvironment - Analysis of the biological characteristics of the malignant transformation of MSCs in tumor microenvironment. **J. Zhu** (Chongqing, P.R. China) (10')
382. The miRNA-mediated effect of TAp73 isoforms on metastasis. S. Galtsidis, **S. Logotheti**, A. Pavlopoulou, B. Vojtesek, V. Zoumpourlis (Athens, Greece; Brno, Czech Republic) (10')

## MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room E, 18:00-20:00  
Saturday, October 11

Chair Persons: Z.G. Ozunal, H. Lohi

504. Drug development, drug repositioning in oncology. **Z.G. Ozunal** (Istanbul, Turkey) (20')
436. Hunting new anxiety genes with the help of man's best friend, the dog. O. Hakosalo, K. Tiira, F. James, T. Jokinen, R. Sarviaho, M. Sillanpää, J. Kere, **H. Lohi** (Helsinki; Oulu, Finland; Ontario, Canada; Huddinge, Sweden) (15')
397. Hepatocyte nuclear factor 4 alpha is a key factor related to depression and physiological homeostasis in the mouse brain. **K. Yamanishi**, N. Doe, M. Sumida, Y. Watanabe, M. Yoshida, W. Li, H. Yamanishi, H. Okamura, H. Matsunaga (Nishinomiya; Akashi; Hirakata, Japan) (15')
561. Surface glycosylation change of hepatocellular carcinoma cell lines HCCLM3 and Hep3B with its enzymatic mechanism. **P. Chen**, H. Wu, Y. Liu, J. Zhou, J. Fan, S. Qiu (Shanghai, P.R. China) (15')
403. Cardiovascular toxicity of targeted therapy. **P.-H. Chu** (Taipei, Taiwan, R.O.C.) (15')
409. Suppression of nascent protein synthesis by natural product berberine. **N. Wang**, H.-Y. Tan, Y. Feng (Shenzhen; Hong Kong, P.R. China) (15')
416. Systematic profiling of mRNA and miRNA expression in the pancreatic islets of diabetic animals. L. Zeng, S. Wei, Y. Sun, W. Qin, J. Cheng, K. Mitchelson, **L. Xie** (Beijing, P.R. China) (15')
404. Radix Dipsaci total saponins increase bone mass in hindlimb unloading rats by regulating osteoblasts and the potential mechanisms. **Y. Niu**, X. Kong, Y. Pan, C. Li, X. Wu, T. Lu, Q. Mei (Xi'an, P.R. China) (10')

POSTERS (Poster viewing during the entire congress)

150. Establishment of MRI traceable oxaliplatin target-delivery nanoparticle conjugate and its therapeutic effects in gastric cancer. **L. Chen**, D. Liu, X. Li, C. Zhou, C. Li (Hangzhou, P.R. China)
164. GSEA of the NF- $\kappa$ B/Snail/YY1/RKIP circuitry in multiple myeloma. **A. Zaravinos**, P. Kanellou, G.I. Lambrou, D.A. Spandidos (Heraklion; Athens, Greece; Stockholm, Sweden)
169. Altered metabolic pathways in clear cell renal cell carcinoma. **A. Zaravinos** (Nicosia, Cyprus; Stockholm, Sweden)
192. Inhibition of angiopoietin-1-induced angiogenesis and lymphangiogenesis by recombinant canstatin and 3-*O*-acetyloleanolic acid. G.P. Hong, J.-H. Park, J. Hwang-Bo, **I.S. Chung** (Yongin, Republic of Korea)
207. Prophylaxis with atorvastatin, pentoxifylline and trans-caryophyllene in chemotherapy-induced leukopenia with 5-fluorouracil in experimental model in rats. M.I.C. Campos, W.D.A. Vieira, F.M. Aarestrup, **B.J.V. Aarestrup** (Juiz de Fora, Brazil)
208. The potential of Trans-caryophyllene, a molecule extracted from the oil of the *Copaifera langsdorffii* tree, in the prevention of oral mucositis and the reduction of systemic inflammatory mediators in rats undergoing chemotherapy with 5-fluorouracil. **M.I.C. Campos**, À.Á.C.D. Presto, F.M. Aarestrup, J.O. do A. Correa, B.J.V. Aarestrup (Juiz de Fora, Brazil)
210. The mRNA expression of HOXA10 gene in glioma. M. Li, N. Lv, C. Du, **Y. Tian** (Changchun, P.R. China)
211. Diagnosis of small cell lung cancer by the rate of Pro gastrin releasing peptide. Y. Yu, W. Xu, K. Ma, **Y. Tian** (Changchun, P.R. China)
212. The study of basic fibroblast growth factor in Hirschsprung's disease. Z. Wang, H. Zhang, Z. Cheng, **Y. Tian** (Changchun, P.R. China)
213. The effect of complement factor H and BF on age-related macular degeneration. L. Ma, J. Hao, G. Su, **Y. Tian** (Changchun, P.R. China)
214. The mRNA expression of HOXC6 gene in glioma. M. Li, N. Lv, C. Du, **Y. Tian** (Changchun, P.R. China)
215. Diagnosis of lung cancer by the combined detection of ProGRP, CEA, SCC-Ag and NSE. Y. Yu, W. Xu, K. Ma, **Y. Tian** (Changchun, P.R. China)
216. The upregulation of HOXD13 gene mRNA expression in glioma cell lines. Z. Cheng, L. Ma, **Y. Tian** (Changchun, P.R. China)
221. Ossification of the cervical ligamentum flavum and osseous brown tumor: Late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma. **E. Gavriilaki**, E. Paschou, O. Tsotsorou, A. Kalaitzoglou, S. Vasileiou, N. Sampanis (Edessa; Thessaloniki, Greece)
222. Acute kidney injury induced by oxaliplatin: A case report and review of the literature. **N. Sampanis**, O. Tsotsorou, E. Gavriilaki, E. Paschou, A. Kalaitzoglou, L. Korelidou, A. Lazaridis, D. Stamatiadis (Serres; Edessa; Thessaloniki, Greece)
226. The study of anti-aging of Zishenyigan pills *in vivo* and *in vitro*. **Y. Liu**, X. Zheng, X. Wang, X. Wang, M. Liu, H. Li, Q. Zhang (Shiyan, P.R. China)
229. Pentraxin 3 is responsive to the activation of CCAAT/enhancer binding delta and promotes cancer progression in the tumor microenvironment. **J.-Y. Chi**, Y.-W. Hsiao, C.-F. Li, Y.-C. Lo, Y.-M. Liu, X. Han, S.-M. Wang, J.-M. Wang (Tainan, Taiwan, R.O.C.)

230. PGE2/HuR/CEBPD axis in macrophages contributes to immunosuppression and inhibits phagocytosis of nasopharyngeal carcinoma. **Y.-W. Hsiao**, J.-Y. Chi, J.-M. Wang (Tainan, Taiwan, R.O.C.)
232. Breast cancer progression is affected by long-term and low-dose exposure to environmental pollutants. C.F. Donini, E. Grisard, V. Maguer-Satta, P. Balaguer, A. Escande, M.-L. Bayle, C. Casellas, B. Combourieu, J. Lachuer, V. Cavailles, T. Philip, B. Fervers, **P.A. Cohen** (Lyon; Montpellier; Valence, France)
235. Different properties of anti-RNP Mab's for Rabies Virus. **V.K. Sologub**, I.A. Koromyslova, S.E. Severin (Moscow, Russia)
239. N-Myc downstream-regulated gene 2 is an Independent Prognostic Factor in Gallbladder Carcinoma. H.-J. Lee, **J.-M. Kim** (Daejeon, Republic of Korea)
244. Mitochondrial division inhibitor-1 modulates mitochondrial morphology and TRAIL sensitivity in human cancer cells. **M. Akita**, M. Suzuki-Karasaki, K. Fujiwara, C. Nakagawa, M. Soma, Y. Yoshida, T. Ochiai, Y. Tokuhashi, Y. Suzuki-Karasaki (Tokyo, Japan)
249. Molecular characterisation of *Streptococcus suis* serotype 2 isolates from Jiangsu. **Z. Tan**, W. Zhou, F. Zhu, F. Tang, Y. Zhu (Nanjing, P.R. China)
257. Redox Regulation of E4TF1-60 by TXN1 through DNA-binding affinity. **B. Baron**, Y. Kuramitsu, T. Kitagawa, K. Nakamura, P. Schembri-Wismayer (Msida, Malta; Ube; Shunan-shi, Japan)
260. The mechanism of Histone deacetylase inhibitor (Suberoylanilide hydroxamic acid) suppresses pancreatic cancer *in vitro*. **B. Yang**, S. Li, Q. Zhou, C. Cao (Changzhou; Suzhou, P.R. China)
261. Anticancer efficacy of combination chemotherapy with CPT-11 + CDGP against human cervical cancer cell lines. **K. Yamamoto** (Osaka, Japan)
263. Anti-cancer activity of fisetin in human non-small lung cancer cells. **K.A. Kang**, M.J. Piao, K.C. Kim, J. Zheng, C.W. Yao, J.W. Cha, J.W. Hyun (Jeju, Republic of Korea)
270. X-linked centronuclear myopathy: Using the yeast *Saccharomyces cerevisiae* to better understand the cellular function of the human Myotubularin MTM1. D.L. Bertazzi, **B. Rinaldi**, J. Laporte, S. Friant (Strasbourg; Illkirch, France)
275. Selective killing of cancer cells by low-temperature atmospheric gas plasma. **K. Saito**, M. Suzuki-Karasaki, N. Fukuda, K. Fujiwara, J. Sahara, T. Asai, H. Koguchi, M. Soma, Y. Suzuki-Karasaki (Tokyo, Japan)
286. Deubiquitination of  $\gamma$ -tubulin by BAP1 prevents chromosome instability in breast cancer cells. **R. Zarrizi**, J. Menard, M. Belting, R. Massoumi (Lund, Sweden)
287. Acquisition of resistance to ionizing radiation in acute promyelocytic leukemia cells occurs via modifications of several mRNA expression networks. **S. Monzen**, R. Saga, M. Chiba, Y. Hosokawa (Hirosaki, Japan)
288. Inhibition of malignant tumor metastasis by 4-methylumbelliferone on X-irradiation. **R. Saga**, S. Monzen, H. Yoshino, M. Chiba, T. Nakamura, Y. Hosokawa (Hirosaki, Japan)
304. The micro fluidic expression of apoptosis genes in relation to resistance in endometrial carcinoma cells. **J. Hatok**, E. Blahovcova, T. Balharek, A. Stefanikova, E. Kudela, E. Babusikova (Martin, Slovakia)
312. Induction of altered cellular response to oxidative stress in HT29 colon cancer cells treated with metformin. **P. Sena**, S. Mancini, F. Mariani, M. Pedroni, M. Benincasa, L. Roncucci (Modena, Italy)



320. Geraniol suppresses prostate cancer growth by downregulating E2F8. **J.N. Chun**, S. Lee, J.-H. Jeon (Seoul, Republic of Korea; Salt Lake City, UT, USA)
326. Human glioblastoma cells response to cytostatics and apoptotic inhibitors treatment *in vitro*. **E. Blahovcova**, P. Racay, D. Dobrota, J. Hatok (Martin, Slovakia)
333. Anticancer and antioxidant activities of grape seed extracts. **J. Sochor**, L. Tomaskova, M. Baron (Brno, Czech Republic)
334. Changes in levels of antioxidant enzymes in prostate cancer cells exposed to effects grape seed extracts. **L. Tomaskova**, J. Sochor, J. Kynicky, M. Baron, M. Masarik (Brno, Czech Republic)
336. Loss of SHP-2 activity in CD4<sup>+</sup> T cells promotes melanoma progression and metastasis. **Y. Shen**, Q. Xu, T. Zhang, W. Guo, Y. Sun, X. Wu, X. Wu, Z. Hua (Nanjing, P.R. China)
343. Spontaneous complete necrosis of hepatocellular carcinoma: A case report and review of the literature. **Y. Takeda**, N. Wakui, Y. Asai, N. Dan, Y. Yamauchi, N. Ueki, T. Otsuka, N. Oba, S. Nishinakagawa, M. Minagawa, Y. Takeda, S. Shiono, T. Kojima (Tokyo, Japan)
344. The mechanism of and treatment for radiation-induced skin injury: Intensification of antioxidant capabilities. **S. Zhang**, J. Luo, J. Cao, J. Xue (Suzhou, P.R. China)
346. Cell-free MALAT1 is associated with the development of cancer-related effusion. **Q. Chen**, X. Qiao, J. Chen, Y. Zhu, Y. Su, M. Yan, X. Cui, H. Shen, S. Tian (Xianyang; Hanzhong, P.R. China)
354. Role of RNA binding protein in cell cycle progression and centrosome maturation in human tumor cells. **Y. Ishigaki**, Y. Nakamura, T. Tatsuno, M. Hashimoto, T. Shimasaki, K. Iwabuchi, N. Tomosugi (Uchinada-machi, Japan)
355. The proliferative effects of Bisphenol A in human MCF7 breast carcinoma cells and prostate LNCaP carcinoma cells. **M. Fickova**, B. Cunderlikova, D. Macejova, J. Brtko, A. Mlynarcikova (Bratislava, Slovak Republic)
356. Cytotoxic effects of tributyltin derivatives and their effects on nuclear retinoic acid/retinoid X receptors and their co-regulator expression in human breast cancer cell line. **J. Brtko**, L. Hunakova, M. Fickova, L. Bialesova, L. Toporova, D. Macejova (Bratislava, Slovak Republic)
357. Effects of two isomers of retinoic acids, calcitriol, Seocalcitol, selected isoflavones and tributyltin chloride on the expression of selected nuclear receptors and genes involved in apoptosis in ACHN human kidney cancer cell line. **D. Macejová** (Bratislava, Slovak Republic)
367. Cladoloside C2 induces apoptosis through the activation of p38 kinase in human leukemia cells. S.-H. Yun, E.-S. Park, V.A. Stonik, J.-Y. Kwak, **J.-I. Park** (Busan, Republic of Korea; Vladivostok, Russia)
383. The anti-proliferative effects of naïve and genetically-modified hMSCs on human cancer cells. I. Christodoulou, A. Kritikos, **V. Zoumpourlis** (Athens, Greece)
384. MiR-200 family miRNAs and miR-205 exhibit a functional role in the progression of the mouse skin carcinogenesis through downregulating specific oncogenes. E. Skourti, S. Logotheti, C.K. Kontos, A. Scorilas, I.P. Trougakos, I. Michalopoulos, **V. Zoumpourlis** (Athens, Greece)
385. Overexpression and role of GPR87 in non-small cell lung carcinoma. **K. Nii**, Y. Tokunaga, D. Liu, J. Nakano, S. Ishikawa, H. Yokomise (Takamatsu, Japan)

386. Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small cell lung cancer: A multicenter phase II study of the Hellenic Oncology Research Group (HORG). **N. Kentepozidis**, A. Kotsakis, C. Nikolaou, G. Nintos, A. Soultati, S. Agelaki, C. Christophyllakis, M. Agelidou, L. Vamvakas, V. Georgoulas (Athens, Greece)
387. Peripheral immunosuppressive cell levels as a predictive marker for the clinical outcome in stage IV colorectal carcinoma. A. Koutoulaki, **N. Kentepozidis**, Z. Zafeiriou, D. Aggouraki, K.E. Vetsika, D. Mavroudis, V. Georgoulas, A. Kotsakis (Heraklion; Athens, Greece)
392. Extracellular microvesicles and cell-to-cell communications in the nervous system. G. Schiera, C.M. Di Liegro, P. Saladino, **I. Di Liegro** (Palermo, Italy)
394. Mapping of receptor tyrosine kinases activation and downstream signaling in rhabdomyosarcoma. **J. Neradil**, R. Veselska, P. Mudry, K. Melicharkova, J. Sterba (Brno, Czech Republic)
398. Methotrexate-dependent changes of DNA methylation and gene expression in osteosarcoma cell lines. **M. Sramek**, J. Neradil, M. Mrkvicova, K. Zitterbart, J. Sterba, R. Veselska (Brno, Czech Republic)
410. The effect of pulsed radiofrequency on dorsal root ganglion and on the  $\beta$ -endorphin levels in the brain and mechanical threshold values of pain in spinal nerve injury rats. **B. Wu**, L. Yang, J. Yue, H. Sun, J. Ni (Beijing, P.R. China)
411. Cervical nerve block affects cytokines and T cell subsets in peripheral blood of patients with cervical discogenic pain. **B. Wu**, Y. Wu, J. Ni (Beijing, P.R. China)
412. Effects of phenylacetate on proliferation and RNA editing deaminase expression of human pancreatic carcinoma BXPc-3 cell lines. G. Zhang, X. Zhang, H. Ren, L. Chen, **T. Jiang** (Changchun, P.R. China)
413. The clinical significance of PTEN protein expression in colorectal carcinoma. X. Zhang, G. Zhang, M. Sun, H. Ren, **T. Jiang** (Changchun, P.R. China)
414. Study on the mechanism of gastric bypass in the treatment of type 2 diabetes mellitus. S. Li, X. Zhang, H. Ren, L. Chen, **T. Jiang** (Changchun, P.R. China)
415. The value of combined detection of carcinoembryonic antigen (CEA) and tumor-associated glycoprotein 72 (TAG-72) in feces in diagnosis of large intestine cancer. H. Ren, G. Zhang, L. Sun, X. Zhang, **T. Jiang** (Changchun, P.R. China)
424. The optimal timing of Strontium-89 combined with zoledronic acid for Japanese breast cancer patients with painful bone metastases. **K. Yamada**, M. Yoshimura, H. Kaise, F. Kimura, M. Hosonaga, K. Miyahara, T. Kawate, Y. Kawai, A. Ueda, N. Kohno, T. Ishikawa (Tokyo, Japan)
427. A common effect of Angiotensin II and Relaxin 2 on normal prostate epithelial cell line - PNT1A. **K. Domińska**, A.W. Piastowska-Ciesielska, Z.E. Matysiak, T. Ochędalski (Lodz, Poland)
428. Expression of AR, AT1-R and KDR in endometrial cancer with different risk of relapse. **A.W. Piastowska-Ciesielska**, K. Domińska, M. Nowakowska, E. Płuciennik, K. Kucharska, K. Wójcik-Krowiranda, A. Bieńkiewicz, A. Bednarek, T. Ochędalski (Lodz, Poland)
429. The influence of *WWOX* gene on invasiveness of estrogen-independent endometrial cancer cell line. **E. Płuciennik**, M. Nowakowska, M. Popęda, K. Pospiech, K. Kośła, I. Baryła, S.-B. Ewa, A.K. Bednarek (Lodz, Poland)
430. *WWOX* tumor suppressor gene influences main cellular processes in human neural stem cells. **K. Kośła**, E. Styczen-Binkowska, M. Nowakowska, K. Pospiech, E. Płuciennik, I. Baryła, A.K. Bednarek (Lodz, Poland)

431. The correlation between *WWOX* tumor suppressor gene and *FOXMI* transcription factor in endometrial cancer and the EMT process. **M. Nowakowska**, E. Płuciennik, M. Gałdyszyńska, K. Pospiech, K. Kośla, I. Baryła, S.-B. Ewa, K. Wójcik-Krowiranda, A. Bienkiewicz, A.K. Bednarek (Lodz, Poland)
432. The biological implications of estrogen receptor status and *WWOX* gene in breast cancer. **K. Pospiech**, M. Nowakowska, E. Płuciennik, K. Kośla, I. Baryła, E. Styczeń-Binkowska, A.K. Bednarek (Lodz, Poland)
435. Role of mesenchymal-associated Pten signaling in intestinal homeostasis and tumorigenesis. **M.-J. Langlois**, F. Maloum, S.B. Roy, K.H. Kaestner, F. Boudreau, N. Rivard, J. Carrier, N. Perreault (Sherbrooke, Canada; Philadelphia, PA, USA)
448. Differential impact of a synthetic peptide derived from the venom of the spider *Lycosa erythrognatha* on proliferative activity of MDA-MB-231 and MCF-7 breast cancer cell lines: A possible correlation with NF- $\kappa$ B pathway activation. **H.W. Huth**, D.M. Dos Santos, H.D. Gravina, F. Quignon, V. Maréchal, M.E. De Lima, C. Ropert (Belo Horizonte/MG, Brazil; Paris, France)
453. Gene expression microarrays reveal gene clusters and biological processes associated with COPD. **D. Kampas**, N. Soultziz, E. Neofytou, D.A. Spandidos, N.M. Sifakas (Heraklion, Greece)
454. Downregulation of Notch signaling pathway in pregnancies complicated by preeclampsia. **P. Fragiadaki**, N. Soultziz, S. Sifakis, D. Koutroulakis, V. Gourvas, N. Vrachnis, D.A. Spandidos (Heraklion; Athens, Greece)
455. Mutation and expression analysis of K-Ras, H-Ras, N-Ras and B-Raf oncogenes in Wilms tumors. **E. Dalpa**, V. Gourvas, N. Soultziz, D.A. Spandidos (Heraklion, Greece)
457. MicroRNA profiling in miscarriage patients. **M.K. Hosseini**, T. Gunel, E. Gumusoglu, H. Ermis, A. Benian, I. Dolekcap, K. Aydinli (Istanbul, Turkey)
463. Epigenetic changes in colorectal cancer. **T.D. Silva**, V.M. Vidigal, A.V. Felipe, R.A. Neto, S.S. Saad, N.M. Forones (São Paulo, Brazil)
472. Proteomic analysis for identification of down-regulated proteins using formalin-fixed paraffin-embedded HCC tissue. **H. Takata**, M. Kudo, R. Wada, W.-X. Peng, K. Ishino, Y. Kawamoto, E. Uchida, Z. Naito (Tokyo, Japan)
476. Proteome analysis of formalin-fixed paraffin-embedded epithelial ovarian cancer tissues. **A. Takaya**, P. Wei-Xia, M. Kudo, T. Yamamoto, K. Ishino, T. Fujii, K. Tezuka, R. Wada, T. Takeshita, Z. Naito (Tokyo; Osaka, Japan)
477. Proteoglycans as potential colon cancer biomarkers. A.V. Suhovskih, A.G. Kondratov, S.V. Aidagulova, V.I. Kashuba, **E.V. Grigorieva** (Novosibirsk, Russia; Kiev, Ukraine)
479. Local inflammation and long-term anti-tumor response after F<sub>2</sub>BMet -PDT. M. Krzykawska-Serda, **K. Jasińska**, M. Elas, G. Stochel, L. Arnaut, K. Urbańska, J.M. Dąbrowski (Krakow, Poland; Coimbra, Portugal)
488. The role of PAK6 in breast cancer. **N. Babteen**, C. Wells, A. Ridley (London, UK)
490. Peptide nucleic acids targeting the murine  $\beta$ -globin mRNAs selectively inhibit hemoglobin production in Murine Erythroleukemia (MEL) cells. G. Montagner, C. Gemmo, E. Fabbri, A. Manicardi, I. Accardo, N. Bianchi, A. Finotti, G. Breveglieri, F. Salvatori, M. Borgatti, I. Lampronti, A. Bresciani, S. Altamura, R. Corradini, **R. Gambari** (Ferrara; Rome, Italy)
491. Antibacterial and anti-inflammatory activity of a Temporin B peptide analogue on an *in vitro* model of cystic fibrosis. V. Bezzeri, C. Avitabile, M.C. Dechecchi, I. Lampronti, M. Borgatti, G. Montagner, G. Cabrini, **R. Gambari**, A. Romanelli (Verona; Napoli; Ferrara, Italy)

494. Regulation of IL-8 gene expression in gliomas by microRNAs. E. Fabbri, E. Brognara, G. Montagner, C. Ghimenton, A. Eccher, C. Cantù, S. Khalil, V. Bezzerri, N. Bianchi, L. Provezza, **A. Finotti**, M.C. Dehecchi, M. Borgatti, M. Chilosi, G. Cabrini, R. Gambari (Ferrara; Verona, Italy)
495. Induction of high levels of apoptosis of temozolomide-resistant T98G glioma cells by co-administration of peptide nucleic acids targeting miR-221 and miR-222. E. Brognara, E. Fabbri, G. Montagner, C. Cantù, A. Manicardi, N. Bianchi, **A. Finotti**, G. Breveglieri, M. Borgatti, R. Corradini, V. Bezzerri, G. Cabrini, R. Gambari (Ferrara; Verona; Parma, Italy)
497. High expression of CUL4A promotes the growth of hepatocellular carcinoma. **X. Yang**, Y. Pan, L. Gao, H. Shan, Y.H. Chen, C. Ma, X. Liang (Jinan, P.R. China)
503. Proteome analysis using formalin-fixed paraffin-embedded keratoacanthoma tissue. **A. Kanzaki**, M. Kudo, S. Ansai, T. Yamamoto, T. Fujii, K. Tezuka, P. Wie-Xia, R. Wada, H. Saeki, Z. Naito (Tokyo; Osaka, Japan)
505. t(8;17)(q22;q21), a new chromosome translocation found in an acute promyelocytic leukemia patient. Y. Song, F. Zhang, C. Zhou, Y. Huan, R. Shen, P. Dong, X. Zhuo, J. Gu, **D. Li** (Nanjing, P.R. China)
512. Matrix metalloproteinases are the HNSCC progression markers. **J. Gumulec**, H. Polanska, M. Sztalmachova, M. Raudenska, H. Binkova, Z. Horakova, R. Kostrica, O. Zitka, R. Kizek, M. Masarik (Brno, Czech Republic)
513. Growth factor expression profile in tumorous tissue of head and neck tumours: Associations with stage and grade. **H. Polanska**, M. Sztalmachova, M. Raudenska, J. Gumulec, H. Binkova, Z. Horakova, R. Kostrica, O. Zitka, R. Kizek, M. Masarik (Brno, Czech Republic)
514. Metallothionein as a key player in neck squamous cell carcinoma origination - A case control study. **M. Sztalmachova**, H. Polanska, M. Raudenska, J. Gumulec, H. Binkova, Z. Horakova, R. Kostrica, O. Zitka, R. Kizek, M. Masarik (Brno, Czech Republic)
522. Identification of differentially reactive antigen biomarkers for prostate cancer screening using protein microarrays. **J.A. Luna-Coronell**, M. Gamperl, R. Kulovics, P. Hofer, A. Gsur, J. Hofbauer, F. Längle, A. Weinhäusel (Vienna; Wiener Neustadt, Austria)
524. A case report of synchronous early gastric adenocarcinoma and gastric mucosa associated with a lymphoid tissue lymphoma. **H. Arai**, T. Matsutani, H. Yoshida, E. Uchida, Z. Naito (Tokyo, Japan)
527. Placental mRNA expression of angiopoietin (Ang)-1 and Ang-2, and their receptor Tie-2 is altered in pregnancies complicated by intrauterine growth restriction. **D. Kappou**, N. Papantoniou, V. Androutsopoulos, A. Konstantinidou, C. Matalliotaki, D.A. Spandidos, S. Sifakis (Athens; Heraklion, Greece)
528. BCL2 expression in patients with endometriosis. **C. Matalliotaki**, M. Andreadaki, Z. Zachou, A. Kalogeraki, S. Sifakis (Heraklion, Greece)
534. The effect of Rho small GTPases signaling in cytoskeleton and motility in human cytomegalovirus (HCMV) infected fibroblasts and glioblastoma cells. M. Tseliou, **S.A. Alarifi**, S.H. Alkahtani, A. Al-Qahtani, N. Goulidaki, G. Sourvinos (Heraklion, Greece; Riyadh, Kingdom of Saudi Arabia)
541. Relationship between Bcl-2 rearrangement and HCV infection in workers exposed to benzene or pesticides: Preliminary observations. **M. Libra**, A. Garozzo, S. Gangemi, C. Costa, L. Fago, A. Marconi, G. Barresi, F. Giambò, R. Salemi, F.M. Pezzino, V. Rapisarda, C. Fenga (Catania; Messina, Italy)
542. Analysis of the RAC1 mutations in cutaneous melanoma patients with occupational sun exposure. **A. Marconi**, M. Libra, S. Gangemi, F. Giambò, F.M. Pezzino, V. Rapisarda, S. Candido, C. Costa, C. Fenga (Catania; Messina, Italy)

544. Jagged-1 expression is downregulated in the skin from biologic-treated psoriatic patients. F. D'Amico, E. Skarmoutsou, **C. Trovato**, G. Lovero, G. Rossi, M.G. Granata, V. Longo, P. Gangemi, G. Malaponte, M. Pettinato, M.C. Mazzarino (Catania, Italy)
545. Lack of association of rs3761549 and rs5902434 polymorphisms of FOXP3 gene with risk of systemic sclerosis in the Italian population: A case-control study. F. D'Amico, **E. Skarmoutsou**, C. Trovato, M. Marchini, G. Malaponte, M. Caronni, R. Scorza, D.A. Spandidos, M.C. Mazzarino (Catania; Milan, Italy; Heraklion, Greece)
546. Exceeding giant hemangioma of liver: Non-surgery managements with interventional ultrasound. **Q. Shi**, W. Fu, G. Chen, H. Zhang, X. Qi, H. Liang, L. Du (Shanghai; Luoyang, P.R. China)
547. Biologically induced improvement of PASI score is associated with a decline of S100A7 expression in psoriatic skin lesions. A preliminary immunohistochemical study. F. D'Amico, E. Skarmoutsou, **C. Trovato**, V. Longo, P. Gangemi, G. Malaponte, M. Pettinato, M.C. Mazzarino (Catania, Italy)
552. Bone marrow-derived mesenchymal stem cells for treatment of experimental colitis. **D. Zuo**, Q. Tang, H. Fan, Z. Shou, X. Liu, D. Cao, Z. Zou (Wuhan, P.R. China)
554. Engineered stem cells expressing carboxyl esterase resulted in the inhibition of tumor growth via migratory property in primary and metastatic lung cancer. **B.-R. Yi**, K.-C. Choi (Cheongju, Republic of Korea)
555. Endometrial cancer was inhibited by the engineered stem cells expressing a therapeutic gene and interferon-beta in a xenograft mouse model. **B.-R. Yi**, K.-C. Choi (Cheongju, Republic of Korea)
556. Treatment of human ovarian cancer cells with dioxin-altered transcriptional levels of aryl-hydrocarbon receptor- and aryl-hydrocarbon receptor-dependent related genes in the presence of estradiol via an estrogen receptor-dependent pathway. **R.-E. Go**, K.-C. Choi (Cheongju, Republic of Korea)
557. Diverse phthalates induced the transcriptional regulation of cell cycle-related genes in human BG-1 ovarian cancer cells expressing estrogen receptors. **R.-E. Go**, K.-C. Choi (Cheongju, Republic of Korea)
558. Treatment with fenhexamid, fludioxonil and cyprodinil resulted in the transcriptional regulation of cytochrome P450 family gene and cell cycle-related genes in human BG-1 cancer cells expressing estrogen receptors. R.-E. Go, **K.-C. Choi** (Cheongju, Republic of Korea)
559. Treatment of MCF-7 breast cancer cells with kaempferol induced the regulation of cell-cycle related and apoptosis-related genes to reverse triclosan-induced cell growth. **S.-H. Kim**, K.-C. Choi (Cheongju, Republic of Korea)
560. Epithelial mesenchymal transition was regulated by bisphenol A via altering related genes in human BG-1 cancer cells expressing estrogen receptors. **Y.-S. Kim**, K.-C. Choi (Cheongju, Republic of Korea)
567. The activity of paraoxonase-1 (PON1) in patients affected by uterine cancer: A preliminary report. K. Gałczynski, M. Bogusiewicz, J. Bełtowski, A. Pyra, T. Rechberger, **A. Semczuk** (Lublin; Nowa Dęba, Poland)
570. Effects induced by glass fibres on human alveolar epithelial cells. C. Ledda, V. Cardile, C. Loreto, G. Mascali, L. Fago, A. Marconi, M. Libra, L. Proietti, **V. Rapisarda** (Catania; Messina, Italy)
573. Micropapillary pattern at the invasive front and its association with unresectable colorectal carcinomas. **N. Akimoto**, T. Fujimori, H. Mitomi, K. Ichikawa, S. Tomita, A. Tatsuguchi, S. Fujimori, Z. Naito, C. Sakamoto (Tokyo; Mibu, Japan)
578. ATM/ATR-dependent regulation of new chromatin-associated protein NFAP7, sustains DNA-damage and carcinogenesis. **M. Normatova**, S. Kattan, R. Babaei-Jadidi, A.S. Nateri (Nottingham, UK)

579. Epigenetically mediated Epithelial-Mesenchymal Transition (EMT) by novel chromatin-associated protein NFAP7. **S. Kattan**, M. Normatova, R. Babaei-Jadidi, A.S. Nateri (Nottingham, UK)
581. Evaluation of histone modification profile in colorectal tumor cell lines with different patterns of DNA methylation. N.T. Dos Santos Doimo, C.M. Lopes-Ramos, L.F. Lima Reis, **R. Bessa Parmigiani** (São Paulo, Brazil)
582. YM155, inhibitor of survivin, suppresses the growth of human leukemia cells. **K.S. Song** (Busan, Republic of Korea)
584. Study of <sup>213</sup>Bi incorporation into porphyrin chelates for applications in  $\alpha$ -radio-immunotherapy. V. Ndoyom, S. Le Gac, P. Remaud-Le Saec, A. Faivre-Chauvet, **B. Boitrel** (Rennes; Nantes, France)
585. Nicotine exposure increases the resistance of cancer cells. **T. Nishioka**, L.-Y. Luo, L. Shen, H. He, A. Mariyannis, T. Sasano, C. Chen (Aoba-ku, Japan; Nanchang, P.R. China; Boston, MA, USA)
593. Can225IgG, a monoclonal antibody targeting EGFR for veterinary oncology. **J. Fazekas**, J. Singer, W. Wang, M. Weichselbaumer, M. Matz, A. Mader, W. Steinfeldner, S. Meitz, D. Mechtcheriakova, Y. Sobanov, M. Willmann, T. Stockner, E. Spillner, R. Kunert, E. Jensen-Jarolim (Vienna, Austria; Beijing, P.R. China; Hamburg, Germany)
595. Matrix metalloproteinase-14 mediates cleavage of syndecan-2. **Y.H. Lee**, J.H. Park, S. Choi, E.-S. Oh, S.-T. Lee (Seoul, Republic of Korea)
603. Expression analysis of p63 and p73 isoforms in urinary bladder cancer. **D. Papadogianni**, N. Soultziz, D.A. Spandidos (Heraklion, Greece)
604. Differences in the expression O-glycosylated glycoproteins in cervical cancer cell lines with and without HPV detected by *Amaranthus leucocarpus* lectin. **C. Solórzano**, Y. Pérez, D. Illescas, J. Cruz, V. Jiménez, Y. Ruíz, A. López, D. Santos, B. Gallegos, E. Zenteno (Oaxaca, México)
605. Role of acetylases and deacetylases in the regulation of cellular energy metabolism and autophagy in cancer. L.H. Hwa, C. Demonacos, **R. Rajendran** (Kuala Lumpur, Malaysia; Manchester, UK)
612. Dissecting the role of curcumin on tumor growth and angiogenesis in mouse model of human breast cancer. **S. Bimonte**, A. Barbieri, G. Palma, D. Rea, A. Luciano, C. Arra (Naples, Italy)